0000727207 false December 31 Q2 2020 P1Y P2Y us-gaap:AccountingStandardsUpdate201613Member 0.0323428 0.0323428 0000727207 2020-01-01 2020-06-30 xbrli:shares 0000727207 2020-08-05 iso4217:USD 0000727207 2020-06-30 0000727207 2019-12-31 iso4217:USD xbrli:shares 0000727207 2020-04-01 2020-06-30 0000727207 2019-04-01 2019-06-30 0000727207 2019-01-01 2019-06-30 0000727207 2018-12-31 0000727207 2019-06-30 0000727207 us-gaap:CommonStockMember 2020-03-31 0000727207 us-gaap:CommonStockMember 2019-03-31 0000727207 us-gaap:CommonStockMember 2019-12-31 0000727207 us-gaap:CommonStockMember 2018-12-31 0000727207 us-gaap:CommonStockMember 2020-04-01 2020-06-30 0000727207 us-gaap:CommonStockMember 2019-04-01 2019-06-30 0000727207 us-gaap:CommonStockMember 2020-01-01 2020-06-30 0000727207 us-gaap:CommonStockMember 2019-01-01 2019-06-30 0000727207 us-gaap:CommonStockMember 2020-06-30 0000727207 us-gaap:CommonStockMember 2019-06-30 0000727207 us-gaap:AdditionalPaidInCapitalMember 2020-03-31 0000727207 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0000727207 us-gaap:AdditionalPaidInCapitalMember 2019-12-31 0000727207 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0000727207 us-gaap:AdditionalPaidInCapitalMember 2020-04-01 2020-06-30 0000727207 us-gaap:AdditionalPaidInCapitalMember 2019-04-01 2019-06-30 0000727207 us-gaap:AdditionalPaidInCapitalMember 2020-01-01 2020-06-30 0000727207 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-06-30 0000727207 us-gaap:AdditionalPaidInCapitalMember 2020-06-30 0000727207 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0000727207 us-gaap:RetainedEarningsMember 2020-03-31 0000727207 us-gaap:RetainedEarningsMember 2019-03-31 0000727207 us-gaap:RetainedEarningsMember 2019-12-31 0000727207 us-gaap:RetainedEarningsMember 2018-12-31 0000727207 us-gaap:RetainedEarningsMember srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2020-03-31 0000727207 us-gaap:RetainedEarningsMember srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2019-03-31 0000727207 us-gaap:RetainedEarningsMember srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2019-12-31 0000727207 us-gaap:RetainedEarningsMember srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2018-12-31 0000727207 us-gaap:RetainedEarningsMember 2020-04-01 2020-06-30 0000727207 us-gaap:RetainedEarningsMember 2019-04-01 2019-06-30 0000727207 us-gaap:RetainedEarningsMember 2020-01-01 2020-06-30 0000727207 us-gaap:RetainedEarningsMember 2019-01-01 2019-06-30 0000727207 us-gaap:RetainedEarningsMember 2020-06-30 0000727207 us-gaap:RetainedEarningsMember 2019-06-30 0000727207 us-gaap:TreasuryStockMember 2020-03-31 0000727207 us-gaap:TreasuryStockMember 2019-03-31 0000727207 us-gaap:TreasuryStockMember 2019-12-31 0000727207 us-gaap:TreasuryStockMember 2018-12-31 0000727207 us-gaap:TreasuryStockMember 2020-06-30 0000727207 us-gaap:TreasuryStockMember 2019-06-30 0000727207 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-03-31 0000727207 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0000727207 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-12-31 0000727207 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0000727207 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-04-01 2020-06-30 0000727207 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-04-01 2019-06-30 0000727207 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-01-01 2020-06-30 0000727207 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-06-30 0000727207 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2020-06-30 0000727207 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0000727207 srt:MinimumMember 2020-01-01 2020-06-30 0000727207 srt:MaximumMember 2020-01-01 2020-06-30 0000727207 axdx:InstrumentsMember 2020-01-01 2020-06-30 0000727207 2020-03-31 0000727207 2019-03-31 0000727207 axdx:PaycheckProtectionProgramCARESActMember us-gaap:UnsecuredDebtMember 2020-04-14 xbrli:pure 0000727207 axdx:TwoPointFiveZeroConvertibleNotesdue2023Member us-gaap:UnsecuredDebtMember 2018-03-27 0000727207 srt:MinimumMember 2020-06-30 0000727207 srt:MaximumMember 2020-06-30 0000727207 us-gaap:RetainedEarningsMember srt:CumulativeEffectPeriodOfAdoptionAdjustmentMember 2020-01-01 0000727207 axdx:FinancialInstitutionAMember us-gaap:CreditConcentrationRiskMember us-gaap:CashAndCashEquivalentsMember 2020-01-01 2020-06-30 0000727207 axdx:FinancialInstitutionBMember us-gaap:CreditConcentrationRiskMember us-gaap:CashAndCashEquivalentsMember 2020-01-01 2020-06-30 0000727207 axdx:FinancialInstitutionCMember us-gaap:CreditConcentrationRiskMember us-gaap:CashAndCashEquivalentsMember 2020-01-01 2020-06-30 0000727207 axdx:FinancialInstitutionAMember us-gaap:CreditConcentrationRiskMember us-gaap:CashAndCashEquivalentsMember 2019-01-01 2019-12-31 0000727207 axdx:FinancialInstitutionBMember us-gaap:CreditConcentrationRiskMember us-gaap:CashAndCashEquivalentsMember 2019-01-01 2019-12-31 0000727207 us-gaap:CustomerConcentrationRiskMember axdx:OneCustomerMember us-gaap:AccountsReceivableMember 2019-01-01 2019-12-31 0000727207 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember axdx:CustomerAMember 2020-04-01 2020-06-30 0000727207 us-gaap:CustomerConcentrationRiskMember us-gaap:SalesRevenueNetMember axdx:CustomerBMember 2019-04-01 2019-06-30 0000727207 us-gaap:CustomerConcentrationRiskMember axdx:CustomerCMember us-gaap:SalesRevenueNetMember 2019-04-01 2019-06-30 0000727207 us-gaap:CustomerConcentrationRiskMember axdx:CustomerDMember us-gaap:SalesRevenueNetMember 2019-01-01 2019-06-30 0000727207 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2020-06-30 0000727207 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2020-06-30 0000727207 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2020-06-30 0000727207 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2020-06-30 0000727207 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2020-06-30 0000727207 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-06-30 0000727207 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-06-30 0000727207 us-gaap:FairValueMeasurementsRecurringMember 2020-06-30 0000727207 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member us-gaap:MutualFundMember 2020-06-30 0000727207 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MutualFundMember 2020-06-30 0000727207 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MutualFundMember 2020-06-30 0000727207 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MutualFundMember 2020-06-30 0000727207 us-gaap:CertificatesOfDepositMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2020-06-30 0000727207 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2020-06-30 0000727207 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2020-06-30 0000727207 us-gaap:CertificatesOfDepositMember us-gaap:FairValueMeasurementsRecurringMember 2020-06-30 0000727207 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member us-gaap:USTreasuryAndGovernmentMember 2020-06-30 0000727207 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2020-06-30 0000727207 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2020-06-30 0000727207 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2020-06-30 0000727207 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-06-30 0000727207 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-06-30 0000727207 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-06-30 0000727207 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-06-30 0000727207 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member us-gaap:CorporateDebtSecuritiesMember 2020-06-30 0000727207 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2020-06-30 0000727207 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2020-06-30 0000727207 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2020-06-30 0000727207 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member us-gaap:MoneyMarketFundsMember 2019-12-31 0000727207 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2019-12-31 0000727207 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2019-12-31 0000727207 us-gaap:FairValueMeasurementsRecurringMember us-gaap:MoneyMarketFundsMember 2019-12-31 0000727207 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member us-gaap:CommercialPaperMember 2019-12-31 0000727207 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2019-12-31 0000727207 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2019-12-31 0000727207 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperMember 2019-12-31 0000727207 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0000727207 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0000727207 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0000727207 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0000727207 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2019-12-31 0000727207 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000727207 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000727207 us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000727207 us-gaap:CertificatesOfDepositMember us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member 2019-12-31 0000727207 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000727207 us-gaap:CertificatesOfDepositMember us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000727207 us-gaap:CertificatesOfDepositMember us-gaap:FairValueMeasurementsRecurringMember 2019-12-31 0000727207 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member us-gaap:USTreasuryAndGovernmentMember 2019-12-31 0000727207 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2019-12-31 0000727207 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2019-12-31 0000727207 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USTreasuryAndGovernmentMember 2019-12-31 0000727207 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-12-31 0000727207 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-12-31 0000727207 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-12-31 0000727207 us-gaap:FairValueMeasurementsRecurringMember us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-12-31 0000727207 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2019-12-31 0000727207 us-gaap:FairValueInputsLevel2Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2019-12-31 0000727207 us-gaap:FairValueInputsLevel3Member us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2019-12-31 0000727207 us-gaap:FairValueMeasurementsRecurringMember us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2019-12-31 0000727207 us-gaap:FairValueMeasurementsRecurringMember us-gaap:FairValueInputsLevel1Member us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0000727207 axdx:TwoPointFiveZeroConvertibleNotesdue2023Member us-gaap:UnsecuredDebtMember 2018-04-04 2018-04-04 0000727207 axdx:TwoPointFiveZeroConvertibleNotesdue2023Member us-gaap:UnsecuredDebtMember 2020-06-30 0000727207 axdx:TwoPointFiveZeroConvertibleNotesdue2023Member us-gaap:UnsecuredDebtMember 2019-12-31 0000727207 us-gaap:CertificatesOfDepositMember 2020-06-30 0000727207 us-gaap:USTreasuryAndGovernmentMember 2020-06-30 0000727207 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2020-06-30 0000727207 us-gaap:CorporateDebtSecuritiesMember 2020-06-30 0000727207 us-gaap:CertificatesOfDepositMember 2019-12-31 0000727207 us-gaap:USTreasuryAndGovernmentMember 2019-12-31 0000727207 us-gaap:USGovernmentAgenciesDebtSecuritiesMember 2019-12-31 0000727207 us-gaap:CommercialPaperNotIncludedWithCashAndCashEquivalentsMember 2019-12-31 0000727207 us-gaap:CorporateDebtSecuritiesMember 2019-12-31 0000727207 us-gaap:ComputerEquipmentMember 2020-06-30 0000727207 us-gaap:ComputerEquipmentMember 2019-12-31 0000727207 us-gaap:TechnologyEquipmentMember 2020-06-30 0000727207 us-gaap:TechnologyEquipmentMember 2019-12-31 0000727207 us-gaap:LeaseholdsAndLeaseholdImprovementsMember 2020-06-30 0000727207 us-gaap:LeaseholdsAndLeaseholdImprovementsMember 2019-12-31 0000727207 axdx:InstrumentsMember 2020-06-30 0000727207 axdx:InstrumentsMember 2019-12-31 0000727207 us-gaap:ConstructionInProgressMember 2020-06-30 0000727207 us-gaap:ConstructionInProgressMember 2019-12-31 0000727207 us-gaap:AssetsLeasedToOthersMember 2020-06-30 0000727207 us-gaap:AssetsLeasedToOthersMember 2019-12-31 0000727207 axdx:NationalInstituteofHealthGrantMember 2015-02-01 2015-02-28 0000727207 2015-02-01 2020-06-30 0000727207 axdx:NationalInstituteofHealthGrantMember 2020-04-01 2020-06-30 0000727207 axdx:NationalInstituteofHealthGrantMember 2019-04-01 2019-06-30 0000727207 axdx:NationalInstituteofHealthGrantMember 2020-01-01 2020-06-30 0000727207 axdx:NationalInstituteofHealthGrantMember 2019-01-01 2019-06-30 0000727207 axdx:ProductsandServicesnotYetDeliveredMember 2020-06-30 0000727207 axdx:ProductsandServicesnotYetDeliveredMember 2019-12-31 axdx:payment 0000727207 axdx:PaycheckProtectionProgramCARESActMember srt:ScenarioForecastMember us-gaap:UnsecuredDebtMember 2020-11-14 2020-11-14 0000727207 axdx:PaycheckProtectionProgramCARESActMember us-gaap:UnsecuredDebtMember 2020-06-30 0000727207 2018-03-27 2018-03-27 0000727207 2018-04-04 2018-04-04 0000727207 axdx:TwoPointFiveZeroConvertibleNotesdue2023Member us-gaap:UnsecuredDebtMember 2018-04-04 0000727207 axdx:TwoPointFiveZeroConvertibleNotesdue2023Member us-gaap:UnsecuredDebtMember us-gaap:LongTermDebtMember 2018-04-04 0000727207 axdx:TwoPointFiveZeroConvertibleNotesdue2023Member us-gaap:AdditionalPaidInCapitalMember us-gaap:UnsecuredDebtMember 2018-04-04 axdx:day 0000727207 2018-04-04 0000727207 us-gaap:RestrictedStockUnitsRSUMember 2020-04-01 2020-06-30 0000727207 us-gaap:RestrictedStockUnitsRSUMember 2019-04-01 2019-06-30 0000727207 us-gaap:RestrictedStockUnitsRSUMember 2020-01-01 2020-06-30 0000727207 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-06-30 0000727207 us-gaap:EmployeeStockOptionMember 2020-04-01 2020-06-30 0000727207 us-gaap:EmployeeStockOptionMember 2019-04-01 2019-06-30 0000727207 us-gaap:EmployeeStockOptionMember 2020-01-01 2020-06-30 0000727207 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-06-30 0000727207 axdx:TwoPointFiveZeroConvertibleNotesdue2023Member us-gaap:UnsecuredDebtMember 2020-01-01 2020-06-30 0000727207 axdx:TwoPointFiveZeroConvertibleNotesdue2023Member us-gaap:UnsecuredDebtMember srt:MaximumMember 2020-01-01 2020-06-30 0000727207 axdx:RestrictedStockUnitsAndRestrictedStockAwardsMember 2019-12-31 0000727207 axdx:RestrictedStockUnitsAndRestrictedStockAwardsMember 2020-01-01 2020-06-30 0000727207 axdx:RestrictedStockUnitsAndRestrictedStockAwardsMember 2020-06-30 0000727207 us-gaap:CostOfSalesMember 2020-04-01 2020-06-30 0000727207 us-gaap:CostOfSalesMember 2019-04-01 2019-06-30 0000727207 us-gaap:CostOfSalesMember 2020-01-01 2020-06-30 0000727207 us-gaap:CostOfSalesMember 2019-01-01 2019-06-30 0000727207 us-gaap:ResearchAndDevelopmentExpenseMember 2020-04-01 2020-06-30 0000727207 us-gaap:ResearchAndDevelopmentExpenseMember 2019-04-01 2019-06-30 0000727207 us-gaap:ResearchAndDevelopmentExpenseMember 2020-01-01 2020-06-30 0000727207 us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-06-30 0000727207 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-04-01 2020-06-30 0000727207 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-04-01 2019-06-30 0000727207 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2020-01-01 2020-06-30 0000727207 us-gaap:SellingGeneralAndAdministrativeExpensesMember 2019-01-01 2019-06-30 0000727207 us-gaap:RestrictedStockUnitsRSUMember 2020-06-30 0000727207 us-gaap:PerformanceSharesMember srt:MinimumMember 2020-01-01 2020-06-30 0000727207 us-gaap:PerformanceSharesMember srt:MaximumMember 2020-01-01 2020-06-30 0000727207 us-gaap:PerformanceSharesMember 2020-01-01 2020-06-30 0000727207 axdx:Grantedin2018Member us-gaap:PerformanceSharesMember srt:MinimumMember 2020-01-01 2020-06-30 0000727207 axdx:Grantedin2018Member us-gaap:PerformanceSharesMember srt:MaximumMember 2020-01-01 2020-06-30 0000727207 us-gaap:PerformanceSharesMember 2018-08-01 2018-08-31 0000727207 us-gaap:PerformanceSharesMember 2020-04-01 2020-04-30 0000727207 us-gaap:PerformanceSharesMember 2019-01-01 2019-06-30 0000727207 axdx:PerformanceBasedRestrictedStockUnitsMember srt:MinimumMember 2020-01-01 2020-06-30 0000727207 srt:MaximumMember axdx:PerformanceBasedRestrictedStockUnitsMember 2020-01-01 2020-06-30 0000727207 axdx:PerformanceBasedRestrictedStockUnitsMember 2020-01-01 2020-06-30 0000727207 axdx:PerformanceBasedRestrictedStockUnitsMember 2020-06-30 axdx:segment 0000727207 us-gaap:GeographicConcentrationRiskMember us-gaap:SalesRevenueNetMember us-gaap:GeographicDistributionForeignMember 2020-04-01 2020-06-30 0000727207 us-gaap:GeographicConcentrationRiskMember us-gaap:SalesRevenueNetMember us-gaap:GeographicDistributionForeignMember 2019-04-01 2019-06-30 0000727207 us-gaap:GeographicConcentrationRiskMember us-gaap:SalesRevenueNetMember us-gaap:GeographicDistributionForeignMember 2020-01-01 2020-06-30 0000727207 us-gaap:GeographicConcentrationRiskMember us-gaap:SalesRevenueNetMember us-gaap:GeographicDistributionForeignMember 2019-01-01 2019-06-30 0000727207 us-gaap:GeographicConcentrationRiskMember us-gaap:AccountsReceivableMember us-gaap:GeographicDistributionForeignMember 2020-06-30 0000727207 us-gaap:GeographicConcentrationRiskMember us-gaap:AccountsReceivableMember us-gaap:GeographicDistributionForeignMember 2019-12-31 0000727207 us-gaap:GeographicDistributionDomesticMember 2020-04-01 2020-06-30 0000727207 us-gaap:GeographicDistributionDomesticMember 2019-04-01 2019-06-30 0000727207 us-gaap:GeographicDistributionDomesticMember 2020-01-01 2020-06-30 0000727207 us-gaap:GeographicDistributionDomesticMember 2019-01-01 2019-06-30 0000727207 us-gaap:GeographicDistributionForeignMember 2020-04-01 2020-06-30 0000727207 us-gaap:GeographicDistributionForeignMember 2019-04-01 2019-06-30 0000727207 us-gaap:GeographicDistributionForeignMember 2020-01-01 2020-06-30 0000727207 us-gaap:GeographicDistributionForeignMember 2019-01-01 2019-06-30 0000727207 axdx:AcceleratePhenoMember 2020-04-01 2020-06-30 0000727207 axdx:AcceleratePhenoMember 2019-04-01 2019-06-30 0000727207 axdx:AcceleratePhenoMember 2020-01-01 2020-06-30 0000727207 axdx:AcceleratePhenoMember 2019-01-01 2019-06-30 0000727207 axdx:OtherRevenueMember 2020-04-01 2020-06-30 0000727207 axdx:OtherRevenueMember 2019-04-01 2019-06-30 0000727207 axdx:OtherRevenueMember 2020-01-01 2020-06-30 0000727207 axdx:OtherRevenueMember 2019-01-01 2019-06-30 0000727207 us-gaap:ProductMember 2020-04-01 2020-06-30 0000727207 us-gaap:ProductMember 2019-04-01 2019-06-30 0000727207 us-gaap:ProductMember 2020-01-01 2020-06-30 0000727207 us-gaap:ProductMember 2019-01-01 2019-06-30 0000727207 us-gaap:ServiceMember 2020-04-01 2020-06-30 0000727207 us-gaap:ServiceMember 2019-04-01 2019-06-30 0000727207 us-gaap:ServiceMember 2020-01-01 2020-06-30 0000727207 us-gaap:ServiceMember 2019-01-01 2019-06-30 0000727207 us-gaap:GeographicConcentrationRiskMember us-gaap:GeographicDistributionDomesticMember us-gaap:PropertyPlantAndEquipmentMember 2020-06-30 0000727207 us-gaap:GeographicConcentrationRiskMember us-gaap:GeographicDistributionDomesticMember us-gaap:PropertyPlantAndEquipmentMember 2019-12-31 0000727207 us-gaap:GeographicConcentrationRiskMember us-gaap:PropertyPlantAndEquipmentMember us-gaap:GeographicDistributionForeignMember 2020-06-30 0000727207 us-gaap:GeographicConcentrationRiskMember us-gaap:PropertyPlantAndEquipmentMember us-gaap:GeographicDistributionForeignMember 2019-12-31 0000727207 us-gaap:GeographicConcentrationRiskMember us-gaap:PropertyPlantAndEquipmentMember 2020-06-30 0000727207 us-gaap:GeographicConcentrationRiskMember us-gaap:PropertyPlantAndEquipmentMember 2019-12-31 0000727207 srt:ChiefOperatingOfficerMember axdx:ConvertibleNoteHolderMember srt:DirectorMember 2019-12-31 0000727207 srt:ChiefOperatingOfficerMember axdx:ConvertibleNoteHolderMember srt:DirectorMember 2020-06-30 0000727207 srt:ChiefOperatingOfficerMember 2019-08-20 2019-08-20 0000727207 2019-08-19 0000727207 2019-08-20 2019-08-20
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
☑ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020
OR
☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____ to _____
Commission file number: 001-31822
ACCELERATE DIAGNOSTICS, INC.
(Exact name of registrant as specified in its charter)

Delaware |  |  | 84-1072256
(State or other jurisdiction |  |  | (I.R.S. Employer Identification No.)
of incorporation or organization) |  |  |
3950 South Country Club Road, |  | Suite 470 |
Tucson, | Arizona |  | 85714
(Address of principal executive offices) |  |  | (Zip Code)

(520) 365-3100
(Registrant’s telephone number, including area code)
N/A
(Former name, former address and former fiscal year, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:

Title of each class | Trading Symbol | Name of each exchange on which registered
Common Stock, $0.001 par | AXDX | The Nasdaq Stock Market LLC
value per share |  | (The Nasdaq Capital Market)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. ☑ Yes ☐ No
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). ☑ Yes ☐ No
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer |  | ☑
Accelerated filer |  | ☐
Non-accelerated filer |  | ☐
Smaller reporting company |  | ☐
Emerging growth company |  | ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). ☐ Yes ☑ No
As of August 5, 2020, there were 56,355,247 shares of the registrant’s common stock outstanding.

TABLE OF CONTENTS

PART I - FINANCIAL INFORMATION |
Item 1. Financial Statements | 3
Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations | 31
Item 3. Quantitative and Qualitative Disclosures About Market Risk | 38
Item 4. Controls and Procedures | 39
Part II - OTHER INFORMATION |
Item 1. Legal Proceedings | 40
Item 1A. Risk Factors | 40
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds | 41
Item 3. Defaults Upon Senior Securities | 41
Item 4. Mine Safety Disclosures | 41
Item 5. Other Information | 41
Item 6. Exhibits | 42

2

PART I - FINANCIAL INFORMATION
Item 1. Financial Statements
ACCELERATE DIAGNOSTICS, INC.
CONDENSED CONSOLIDATED
BALANCE SHEET
(in thousands, except share data)

| June 30, | December 31,
| 2020 | 2019
| Unaudited |
ASSETS |  |
Current assets: |  |
Cash and cash equivalents | $ | 47,368 |  | $ | 61,014 |
Investments | 41,326 |  | 47,437 |
Trade accounts receivable | 2,592 |  | 3,222 |
Inventory | 8,723 |  | 8,059 |
Prepaid expenses | 1,400 |  | 955 |
Other current assets | 1,099 |  | 1,165 |
Total current assets | 102,508 |  | 121,852 |
Property and equipment, net | 8,004 |  | 7,905 |
Right of use assets | 3,569 |  | 3,917 |
Other non-current assets | 734 |  | 750 |
Total assets | $ | 114,815 |  | $ | 134,424 |
LIABILITIES AND STOCKHOLDERS’ EQUITY |  |
Current liabilities: |  |
Accounts payable | $ | 2,702 |  | $ | 2,351 |
Accrued liabilities | 3,346 |  | 3,828 |
Accrued interest | 1,262 |  | 1,262 |
Deferred revenue | 232 |  | 271 |
Current portion of long-term debt | 2,129 |  | — |
Current operating lease liability | 447 |  | 450 |
Total current liabilities | 10,118 |  | 8,162 |
Non-current operating lease liability | 3,366 |  | 3,579 |
Other non-current liabilities | 190 |  | 19 |
Long-term debt | 2,662 |  | — |
Convertible notes | 135,469 |  | 130,043 |
Total liabilities | $ | 151,805 |  | $ | 141,803 |
Commitments and contingencies |  |
Stockholders’ deficit: |  |
Preferred shares, $0.001 par value; |  |
5,000,000 preferred shares authorized and none outstanding as of June 30, 2020 and December 31, 2019 | — |  | — |
Common stock, $0.001 par value; |  |
85,000,000 common shares authorized with 56,249,482 shares issued and outstanding on June 30, 2020 and 85,000,000 common shares authorized with 54,708,792 shares issued and outstanding on December 31, 2019 | 56 |  | 55 |
Contributed capital | 463,178 |  | 452,344 |
Treasury stock | (45,067) |  | (45,067) |
Accumulated deficit | (455,297) |  | (414,653) |
Accumulated other comprehensive income (loss) | 140 |  | (58) |
Total stockholders’ deficit | (36,990) |  | (7,379) |
Total liabilities and stockholders’ deficit | $ | 114,815 |  | $ | 134,424 |

See accompanying notes to condensed consolidated financial statements.
3

ACCELERATE DIAGNOSTICS, INC.
CONDENSED CONSOLIDATED
STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
Unaudited
(in thousands, except per share data)

| Three Months Ended |  |  | Six Months Ended |
| June 30, | June 30, |  | June 30, | June 30,
| 2020 | 2019 |  | 2020 | 2019
Net sales | $ | 2,125 |  | $ | 1,806 |  |  | $ | 4,468 |  | $ | 3,557 |
Cost of sales | 1,171 |  | 907 |  |  | 2,459 |  | 1,823 |
Gross profit | 954 |  | 899 |  |  | 2,009 |  | 1,734 |
Costs and expenses: |  |  |  |  |
Research and development | 5,347 |  | 6,149 |  |  | 11,189 |  | 13,083 |
Sales, general and administrative | 11,332 |  | 12,837 |  |  | 24,275 |  | 25,559 |
Total costs and expenses | 16,679 |  | 18,986 |  |  | 35,464 |  | 38,642 |
Loss from operations | (15,725) |  | (18,087) |  |  | (33,455) |  | (36,908) |
Other income (expense): |  |  |  |  |
Interest expense | (3,835) |  | (3,528) |  |  | (7,584) |  | (6,987) |
Foreign currency exchange gain (loss) | 91 |  | 6 |  |  | (37) |  | (53) |
Interest income | 224 |  | 812 |  |  | 604 |  | 1,653 |
Other income (expense), net | 15 |  | (1) |  |  | (67) |  | (3) |
Total other expense, net | (3,505) |  | (2,711) |  |  | (7,084) |  | (5,390) |
Net loss before income taxes | (19,230) |  | (20,798) |  |  | (40,539) |  | (42,298) |
Provision for income taxes | — |  | (17) |  |  | — |  | (238) |
Net loss | $ | (19,230) |  | $ | (20,815) |  |  | $ | (40,539) |  | $ | (42,536) |
Basic and diluted net loss per share | $ | (0.35) |  | $ | (0.38) |  |  | $ | (0.74) |  | $ | (0.78) |
Weighted average shares outstanding | 55,445 |  | 54,476 |  |  | 55,139 |  | 54,407 |
Other comprehensive loss: |  |  |  |  |
Net loss | $ | (19,230) |  | $ | (20,815) |  |  | $ | (40,539) |  | $ | (42,536) |
Net unrealized gain (loss) on debt securities available-for-sale | (44) |  | 98 |  |  | 179 |  | 219 |
Foreign currency translation adjustment | 34 |  | 50 |  |  | 19 |  | (26) |
Comprehensive loss | $ | (19,240) |  | $ | (20,667) |  |  | $ | (40,341) |  | $ | (42,343) |

See accompanying notes to condensed consolidated financial statements.
4

ACCELERATE DIAGNOSTICS, INC.
CONDENSED CONSOLIDATED
STATEMENTS OF CASH FLOWS
Unaudited
(in thousands)

| Six Months Ended |
| June 30, | June 30,
| 2020 | 2019
Cash flows from operating activities: |  |
Net loss | $ | (40,539) |  | $ | (42,536) |
Adjustments to reconcile net loss to net cash used in operating activities: |  |
Depreciation and amortization | 1,571 |  | 1,236 |
Amortization of investment discount | 13 |  | (320) |
Equity-based compensation | 7,615 |  | 6,278 |
Amortization of debt discount and issuance costs | 5,426 |  | 4,843 |
Realized loss on sale of investments | 3 |  | — |
Loss on disposal of property and equipment | 527 |  | 407 |
Contributions to deferred compensation plan | (160) |  | — |
(Increase) decrease in assets: |  |
Accounts receivable | 550 |  | (51) |
Inventory | (1,979) |  | (2,217) |
Prepaid expense and other | (363) |  | (588) |
Increase (decrease) in liabilities: |  |
Accounts payable | 390 |  | 476 |
Accrued liabilities, and other | (581) |  | (1,110) |
Deferred revenue and income | (39) |  | 38 |
Deferred compensation | 171 |  | (18) |
Net cash used in operating activities | (27,395) |  | (33,562) |
Cash flows from investing activities: |  |
Purchases of equipment | (643) |  | (76) |
Purchase of marketable securities | (21,509) |  | (17,601) |
Proceeds from sales of marketable securities | — |  | 13,400 |
Maturities of marketable securities | 27,844 |  | 54,447 |
Net cash provided by investing activities | 5,692 |  | 50,170 |
Cash flows from financing activities: |  |
Proceeds from issuance of common stock | 216 |  | 251 |
Proceeds from exercise of options | 3,031 |  | 4,369 |
Proceeds from debt | 4,791 |  | — |
Net cash provided by financing activities | 8,038 |  | 4,620 |
Effect of exchange rate on cash | 19 |  | (19) |
(Decrease) increase in cash and cash equivalents | (13,646) |  | 21,209 |
Cash and cash equivalents, beginning of period | 61,014 |  | 66,260 |
Cash and cash equivalents, end of period | $ | 47,368 |  | $ | 87,469 |

See accompanying notes to condensed consolidated financial statements.
5

ACCELERATE DIAGNOSTICS, INC.
CONDENSED CONSOLIDATED
STATEMENTS OF CASH FLOWS (CONTINUED)
Unaudited
(in thousands)

| Six Months Ended |
| June 30, | June 30,
| 2020 | 2019
Non-cash investing activities: |  |
Net transfer of instruments from inventory to property and equipment | $ | 1,288 |  | $ | 1,715 |
Supplemental cash flow information: |  |
Interest paid | $ | 2,144 |  | $ | 2,144 |
Income taxes paid, net of refunds | $ | 26 |  | $ | 9 |

See accompanying notes to condensed consolidated financial statements.
6

ACCELERATE DIAGNOSTICS, INC.
CONDENSED CONSOLIDATED
STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)
Unaudited
(in thousands)

| Three Months Ended |  |  | Six Months Ended |
| June 30, |  |  | June 30, |
| 2020 | 2019 |  | 2020 | 2019
Common stock shares outstanding |  |  |  |  |
Beginning | 54,994 |  | 54,454 |  |  | 54,709 |  | 54,232 |
Exercise of options | 1,247 |  | 53 |  |  | 1,517 |  | 268 |
Issuance of common stock under employee purchase plan | 8 |  | 5 |  |  | 23 |  | 12 |
Ending | 56,249 |  | 54,512 |  |  | 56,249 |  | 54,512 |
Common stock |  |  |  |  |
Beginning | $ | 55 |  | $ | 54 |  |  | $ | 55 |  | $ | 54 |
Exercise of Options | 1 |  | 1 |  |  | 1 |  | 1 |
Ending | $ | 56 |  | $ | 55 |  |  | $ | 56 |  | $ | 55 |
Contributed capital |  |  |  |  |
Beginning | $ | 457,987 |  | $ | 440,154 |  |  | $ | 452,344 |  | $ | 432,885 |
Exercise of options | 1,713 |  | 692 |  |  | 3,031 |  | 4,369 |
Issuance of common stock under employee purchase plan | 104 |  | 111 |  |  | 215 |  | 250 |
Equity-based compensation | 3,374 |  | 2,900 |  |  | 7,588 |  | 6,353 |
Ending | $ | 463,178 |  | $ | 443,857 |  |  | $ | 463,178 |  | $ | 443,857 |

See accompanying notes to condensed consolidated financial statements.
7

ACCELERATE DIAGNOSTICS, INC.
CONDENSED CONSOLIDATED
STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) (CONTINUED)
Unaudited
(in thousands)

| Three Months Ended |  |  | Six Months Ended |
| June 30, |  |  | June 30, |
| 2020 | 2019 |  | 2020 | 2019
Accumulated deficit |  |  |  |  |
Beginning | $ | (436,067) |  | $ | (352,069) |  |  | $ | (414,653) |  | $ | (330,348) |
Cumulative effect of accounting changes | — |  | — |  |  | (105) |  | — |
Net loss | (19,230) |  | (20,815) |  |  | (40,539) |  | (42,536) |
Ending | $ | (455,297) |  | $ | (372,884) |  |  | $ | (455,297) |  | $ | (372,884) |
Treasury stock |  |  |  |  |
Beginning | $ | (45,067) |  | $ | (45,067) |  |  | $ | (45,067) |  | $ | (45,067) |
Ending | $ | (45,067) |  | $ | (45,067) |  |  | $ | (45,067) |  | $ | (45,067) |
Accumulated other comprehensive (loss) income |  |  |  |  |
Beginning | $ | 150 |  | $ | (104) |  |  | $ | (58) |  | $ | (149) |
Net unrealized gain on debt securities available-for-sale | (44) |  | 98 |  |  | 179 |  | 219 |
Foreign currency translation adjustment | 34 |  | 50 |  |  | 19 |  | (26) |
Ending | $ | 140 |  | $ | 44 |  |  | $ | 140 |  | $ | 44 |
Total stockholders' equity (deficit) | $ | (36,990) |  | $ | 26,005 |  |  | $ | (36,990) |  | $ | 26,005 |

See accompanying notes to condensed consolidated financial statements.
8

ACCELERATE DIAGNOSTICS, INC.
NOTES TO THE CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
Unaudited
NOTE 1. ORGANIZATION AND NATURE OF BUSINESS; BASIS OF PRESENTATION; PRINCIPLES OF CONSOLIDATION; SIGNIFICANT ACCOUNTING POLICIES
Accelerate Diagnostics, Inc. (“we” or “us” or “our” or “Accelerate” or the “Company”) is an in vitro diagnostics company dedicated to providing solutions that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections.
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with U.S. Generally Accepted Accounting Principles (“U.S. GAAP”) and applicable rules and regulations of the U.S. Securities and Exchange Commission (“SEC”) regarding interim financial reporting. Certain information and note disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been condensed or omitted pursuant to such rules and regulations. Therefore, these condensed consolidated financial statements should be read in conjunction with the condensed consolidated financial statements and notes included in our Annual Report on Form 10-K for the fiscal year ended December 31, 2019, as filed with the SEC on February 28, 2020.
The condensed consolidated balance sheet as of December 31, 2019 included herein was derived from the audited financial statements as of that date, but does not include all disclosures such as notes required by U.S. GAAP.
The accompanying unaudited condensed consolidated financial statements reflect all normal recurring adjustments necessary to present fairly the financial position, results of operations, and cash flows for the interim periods presented, but are not necessarily indicative of the results of operations to be anticipated for the entire year ending December 31, 2020, or any future period.
All amounts are rounded to the nearest thousand dollars unless otherwise indicated.
Principles of Consolidation
The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiaries after elimination of intercompany transactions and balances.
Use of Estimates
The preparation of the Company’s condensed consolidated financial statements requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and the related disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The more significant areas requiring the use of management estimates and assumptions relate to accounts receivable, inventory, property and equipment, accrued liabilities, warranty liabilities, tax valuation accounts and equity–based compensation. Actual results could differ materially from those estimates.
Estimated Fair Value of Financial Instruments
The Company follows Accounting Standards Codification (“ASC”) 820, Fair Value Measurement, which has defined fair value and requires the Company to establish a framework for measuring and disclosing fair value. The framework requires the valuation of assets and liabilities subject to fair value measurements using a three tiered approach and fair value measurement be classified and disclosed in one of the following three categories:
•Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities;
9

•Level 2: Quoted prices for similar assets and liabilities in active markets, quoted prices in markets that are not active, or inputs that are observable, either directly or indirectly, for substantially the full term of the asset or liability;
•Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e. supported by little or no market activity).
The carrying amounts of financial instruments such as cash and cash equivalents, trade accounts receivable, prepaid expenses, other current assets, accounts payable, accrued liabilities, and other current liabilities approximate the related fair values due to the short-term maturities of these instruments.
The estimated fair value of the Company’s convertible note represents a Level 2 measurement. See Note 11, Convertible Notes for further detail on the Company’s convertible notes.
The estimated fair value of the Company’s long-term debt represents a Level 3 measurement, as the Loan is privately held with no public market. The carrying amount of the Loan approximates fair value due to the short-term nature of this instrument. See Note 10, Long-Term Debt for further detail on the Company’s long-term debt.
Cash and Cash Equivalents
All highly liquid investments with an original maturity of three months or less at time of purchase are considered to be cash equivalents. Cash and cash equivalents include overnight repurchase agreement accounts and other investments. As part of our cash management process, excess operating cash is invested in overnight repurchase agreements with our bank. Repurchase agreements and other investments classified as cash and cash equivalents are not deposits and are not insured by the U.S. Government, the FDIC or any other government agency and involve investment risk including possible loss of principal. We believe, however, that the market risk arising from holding these financial instruments is minimal.
Investments
The Company invests in various debt securities available-for-sale and equity securities which are primarily held in the custody of major financial institutions. Debt securities available-for-sale consist of certificates of deposit, U.S. government and agency securities, commercial paper, asset-backed securities, and corporate notes and bonds. Equity securities consist of mutual funds. The Company records these investments in the condensed consolidated balance sheet at fair value. Unrealized gains or losses for debt securities available-for-sale are included in accumulated other comprehensive income (loss), a component of stockholders’ equity. Unrealized gains or losses for equity securities are included in other income (expense), net, a component of statements of operations and comprehensive loss. The Company considers all debt securities available-for-sale, including those with maturity dates beyond 12 months, as available to support current operational liquidity needs. The Company classifies its investments as current based on the nature of the investments and their availability for use in current operations.
On a quarterly basis, we perform an assessment to determine whether there have been any events or economic circumstances to indicate that a debt security available-for-sale in an unrealized loss position has suffered impairment as a result of credit loss or other factors. A debt security available-for-sale is considered impaired if its fair value is less than its amortized cost basis at the reporting date.
If we intend to sell the debt security or if it is more-likely-than-not that we will be required to sell the debt security before the recovery of its amortized cost basis, the impairment is recognized and the unrealized loss is recorded as a direct write-down of the security's amortized cost basis with an offsetting entry to earnings. If we do not intend to sell the debt security or believe we will not be required to sell the debt security before the recovery of its amortized cost basis, the impairment is assessed to determine if a credit loss component exists. We use a discounted cash flow method to determine the credit loss component. In the event a credit loss exists, an allowance for credit losses is recorded in earnings for the credit loss component of the impairment while the remaining portion of the impairment attributable to factors other than credit loss is recognized, net of tax, in accumulated other comprehensive income (loss). The amount of impairment recognized due to credit factors is limited to the excess of the amortized cost basis over the fair value of the security available-for-sale.
10

Inventory
Inventory is stated at the lower of cost or net realizable value. The Company determines the cost of inventory using the first-in, first out method. The Company estimates the recoverability of inventory by reference to internal estimates of future demands and product life cycles, including expiration. The Company periodically analyzes its inventory levels to identify inventory that may expire prior to expected sale or has a cost basis in excess of its estimated realizable value and records a charge to expense for such inventory as appropriate.
Accounts Receivable
Accounts receivable consist of amounts due to the Company for sales to customers and are based on what we expect to collect in exchange for goods and services. Receivables are considered past due based on the contractual payment terms and are written off if reasonable collection efforts prove unsuccessful.
We maintain an allowance for credit losses for expected uncollectible accounts receivable, which is recorded as an offset to accounts receivable and changes in such are classified as general and administrative expense in the condensed consolidated statements of operations. We assess collectibility by reviewing accounts receivable on a collective basis where similar characteristics exist and on an individual basis when we identify specific customers with known disputes or collectibility issues. In determining the amount of the allowance for credit losses, we consider historical collectibility and make judgments about the creditworthiness of customers based on credit evaluations. We also consider customer-specific information, current market conditions and reasonable and supportable forecasts of future economic conditions to inform adjustments to historical loss data. The allowance for credit losses as of June 30, 2020 was $0.1 million.
Property and Equipment
Property and equipment are recorded at cost. Maintenance and repairs are charged to expense as incurred and expenditures for major improvements are capitalized. Gains and losses from retirement or replacement are included in costs and expenses. Depreciation of property and equipment is computed using the straight-line method over the estimated useful life of the assets, ranging from one to seven years. Leasehold improvements are depreciated over the remaining life of the lease or the life of the asset, whichever is less.
Instruments Classified as Property and Equipment
Property and equipment includes Accelerate Pheno systems (also referred to as instruments) used for sales demonstrations, instruments under rental agreements and instruments used for research and development. Depreciation expense for instruments used for sales demonstrations is recorded as a component of sales, general and administrative expense. Depreciation expense for instruments placed at customer sites pursuant to reagent rental agreements is recorded as a component of cost of sales. Depreciation expense for instruments used in our laboratory and research is recorded as a component of research and development expense. The Company retains title to these instruments and depreciates them over five years. Losses from the retirement of returned instruments are included in costs and expenses.
The Company evaluates the recoverability of the carrying amount of its instruments whenever events or changes in circumstances indicate that the carrying amount of the assets may not be recoverable, and this evaluation is performed at least annually. This evaluation is based on our estimate of future cash flows and the estimated fair value of such long-lived assets, and provides for impairment if such undiscounted cash flows or the estimated fair value are insufficient to recover the carrying amount of instruments. No impairment charges have been recorded as of June 30, 2020 and December 31, 2019.
Long-lived Assets
Long-lived assets and certain identifiable intangibles to be held and used by the Company are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. The Company continuously evaluates the recoverability of its long-lived assets based on estimated future cash flows from and the estimated fair value of such long-lived assets, and provides for impairment if such undiscounted cash flows or the estimated fair value are insufficient to recover the carrying amount of the long-lived asset.
11

Warranty Reserve
Instruments are typically sold with a one year limited warranty, while kits and accessories are typically sold with a sixty days limited warranty. Accordingly, a provision for the estimated cost of the limited warranty repair is recorded at the time revenue is recognized. Our estimated warranty provision is based on our estimate of future repair events and the related estimated cost of repairs. The Company periodically assesses the adequacy of the warranty reserve and adjusts the amount as necessary. The expense incurred for these provisions is included in cost of sales on the condensed consolidated statements of operations and comprehensive loss.
Warranty reserve activity for the three and six months ended June 30, 2020 and 2019 is as follows (in thousands):

| Three Months Ended June 30, |  |  | Six Months Ended June 30, |
| 2020 | 2019 |  | 2020 | 2019
Beginning balance | $ | 342 |  | $ | 206 |  |  | $ | 403 |  | $ | 215 |
Provisions | — |  | — |  |  | — |  | 70 |
Warranty cost incurred | (37) |  | (10) |  |  | (98) |  | (89) |
Ending balance | $ | 305 |  | $ | 196 |  |  | $ | 305 |  | $ | 196 |

Paycheck Protection Program (PPP) Loan
The PPP was established by the Coronavirus Aid, Relief, and Economic Security (“CARES”) Act, through a significant expansion of the Small Business Administration (“SBA”) 7(a) loan program. On April 14, 2020, the Company entered into a promissory note (the “PPP Note”) evidencing an unsecured loan in the amount of $4.8 million.
The Company elected to account for the PPP Note in accordance with ASC 470, Debt, with interest accrued in accordance with the interest method under ASC 835-30, Imputation of Interest. The Company recognized the entire PPP Note amount as a liability on the balance sheet, with interest accrued and expensed over the term of the loan. The Company did not impute additional interest at a market rate because transactions where interest rates are prescribed by governmental agencies are excluded from the scope of ASC 835-30.
The PPP Note will remain a liability until either of the following criteria are met:
•The Company has been legally released from being the primary obligor under the liability (i.e. the PPP Note is for-given)
•The Company pays the lender and is relieved of its obligation for the liability
See Note 10, Long-Term Debt for further detail regarding the PPP Note.
Convertible Notes
The Company accounts for convertible debt instruments that may be settled in cash or equity upon conversion, which includes the 2.50% Senior Convertible Notes due 2023 (the “Notes”), by separating the liability and equity components of the instruments in a manner that reflects our nonconvertible debt borrowing rate. The Company determined the carrying amount of the liability component of the Notes by using estimates and assumptions that market participants would use in pricing a debt instrument. These estimates and assumptions are judgmental in nature and could have a significant impact on the determination of the debt component, and the associated non-cash interest expense.
The equity component is treated as a discount on the liability component of the Notes, which is amortized over the term of the Notes using the effective interest rate method. Debt issuance costs related to the Notes are allocated to the liability and equity components of the Notes based on their relative values. Debt issuance costs allocated to the liability component are amortized over the life of the Notes as additional non-cash interest expense. Transaction costs allocated to equity are netted with the equity component of the convertible debt instrument in stockholders’ deficit.
12

Revenue Recognition
The Company recognizes revenue when control of the promised good or service is transferred to our customers in an amount that reflects the consideration we expect to be entitled to in exchange for those goods or services. Sales taxes are excluded from revenues.
The Company determines revenue recognition through the following steps:
•Identification of the contract with a customer
•Identification of the performance obligations in the contract
•Determination of the transaction price
•Allocation of the transaction price to the performance obligations
•Recognition of revenue as we satisfy a performance obligation
Product revenue is derived from the sale or rental of our instruments and sales of related consumable products. When an instrument is sold, revenue is generally recognized upon installation of the unit consistent with contract terms, which do not include a right of return. When a consumable product is sold, revenue is generally recognized upon shipment. Invoices are generally issued when revenue is recognized and the term between invoicing and when payment is due is not typically significant.
Service revenue is derived from the sale of extended service agreements which are generally non-cancellable. This revenue is recognized on a straight-line basis over the contract term beginning on the effective date of the contract because the Company is standing ready to provide services. Invoices are generally issued annually and coincide with the beginning of individual service terms.
Our contracts with customers may include multiple performance obligations. For such arrangements, we allocate revenue to each performance obligation based on its relative standalone selling price. We generally determine relative standalone selling prices based on the price charged to customers for each individual performance obligation.
Sales commissions earned by our sales force are considered incremental and recoverable costs of obtaining a contract with a customer. The Company has determined these costs would have an amortization period of less than one year and has elected to recognize them as an expense when incurred. Contract asset opening and closing balances were immaterial for the three and six months ended June 30, 2020.
Cost of Sales
Cost of sales includes cost of materials, direct labor, equity-based compensation, facility and other manufacturing overhead costs for consumable tests and instruments sold to customers. Cost of sales for instruments also includes depreciation on revenue generating instruments that have been placed with our customers under a reagent rental agreement. Cost of sales includes repair and maintenance cost for instruments covered by a service agreement or instruments covered by a reagent rental agreement. Cost of sales also includes warranty related expenses.
Shipping and Handling
Shipping and handling costs billed to customers are included as a component of revenue. The corresponding expense incurred with third party carriers is included as a component of sales, general and administrative costs on the condensed consolidated statements of operations and comprehensive loss.
Leases
The Company accounts for commercial leases in accordance with ASC 842, Leases. We determine if an arrangement is or contains a lease and the type of lease at inception. The Company classifies commercial leases
13

as finance leases (lessee) or sales-type leases (lessor) when there is either a transfer of ownership of the underlying asset by the end of the lease term, the lease contains an option to purchase the asset that we are reasonably certain will be exercised, the lease term is for the major part of the remaining economic life of the asset, the present value of the lease payments and any residual value guarantee equals or substantially exceeds all the fair value of the asset, or the asset is of such a specialized nature that it will have no alternative use to the lessor at the end of the lease term. Payments contingent on future events (i.e. based on usage) are considered variable and excluded from lease payments for the purposes of classification and initial measurement. Several of our leases include options to renew or extend the term upon mutual agreement of the parties and others include one-year extensions exercisable by the lessee. None of our leases contain residual value guarantees, restrictions, or covenants.
To determine whether a contract contains a lease, the Company uses its judgment in assessing whether the lessor retains a material amount of economic benefit from an underlying asset, whether explicitly or implicitly identified, which party holds control over the direction and use of the asset, and whether any substantive substitution rights over the asset exist.
Lessee
Operating leases are included in right-of-use (“ROU”) assets and operating lease liabilities within our consolidated balance sheets. These assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. ROU assets and their related liabilities are recognized at commencement date based on the present value of lease payments over the lease term. Typically, we use our incremental borrowing rate based on the information available at commencement in determining the present value of lease payments. We use the implicit rate when readily determinable. ROU assets are net of lease payments made and exclude lease incentives. Lease expense for lease payments is recognized on a straight-line basis over the lease term, which may include options to extend or terminate the lease when it is reasonably certain that we will exercise the option. As of June 30, 2020 and December 31, 2019, the Company was not party to finance lease arrangements.
Our operating leases consist primarily of leased office, factory, and laboratory space in the U.S. and office space in Europe, have between two and six-year terms, and typically contain penalizing, early-termination provisions.
Lessor
The Company leases instruments to customers under “reagent rental” agreements, whereby the customer agrees to purchase consumable products over a stated term, typically five years or less, for a volume-based price that includes an embedded rental for the instruments. When collectibility is probable, that amount is recognized as income at lease commencement for sales-type leases and as product is shipped, typically in a straight–line pattern, over the term for operating leases, which typically include a termination without cause or penalty provision given a short notice period.
Consideration is allocated between lease and non-lease components based on stand-alone selling price in accordance with ASC 606, Revenue from Contracts with Customers.
Net investment in sales-type leases are included within our condensed consolidated balance sheets as a component of other current assets and other non-current assets, which include the present value of lease payments not yet received and the present value of the residual asset, which are determined using the information available at commencement, including the lease term, estimated useful life, rate implicit in the lease, and expected fair value of the instrument.
Nonqualified Cash Deferral Plan
The Company's Cash Deferral Plan (the “Deferral Plan”), provides certain key employees, with an opportunity to defer the receipt of such participant's base salary. The Deferral Plan is intended to be a nonqualified deferred compensation plan that complies with the provisions of Section 409A of the Internal Revenue Code. All of the investments held in the Deferral Plan are equity securities consisting of mutual funds and recorded at fair value with changes in the investments' fair value recognized as earnings in the period they occur. The corresponding liability for the Deferral Plan is included in other non-current liabilities in the condensed consolidated balance sheet.
14

Equity-Based Compensation
The Company may award stock options, restricted stock units (“RSUs”), performance-based awards, and other equity-based instruments to its employees, directors and consultants. Compensation cost related to equity-based instruments is based on the fair value of the instrument on the grant date, and is recognized over the requisite service period on a straight-line basis over the vesting period for each tranche (an accelerated attribution method) except for performance-based awards. Performance-based awards vest based on the achievement of performance targets. Compensation costs associated with performance-based awards are recognized over the requisite service period based on probability of achievement. Performance-based awards require management to make assumptions regarding the likelihood of achieving performance targets.
The Company estimates the fair value of service based and performance based stock option awards, including modifications of stock option awards, using the Black-Scholes option pricing model. This model derives the fair value of stock options based on certain assumptions related to expected stock price volatility, expected option life, risk-free interest rate and dividend yield.
•Volatility: The expected volatility is based on the historical volatility of the Company's stock price over the most recent period commensurate with the expected term of the stock option award.
•Expected term: The estimated expected term for employee awards is based on the calculation published by the SEC in SAB110 for use when there is not a sufficient history of employee exercise patterns. For consultant awards, the estimated expected term is the same as the life of the award.
•Risk-free interest rate: The risk-free interest rate is based on published U.S. Treasury rates for a term commensurate with the expected term.
•Dividend yield: The dividend yield is estimated as zero as the Company has not paid dividends in the past and does not have any plans to pay any dividends in the foreseeable future.
The Company records the fair value of RSUs or stock grants based on published closing market price on the day before the grant date. The Company accounts for forfeitures as they occur rather than on an estimated basis.
Deferred Tax Assets
Deferred tax assets and liabilities are recorded for the estimated future tax effects of temporary differences between the tax basis of assets and liabilities and amounts reported in the accompanying balance sheets. The change in deferred tax assets and liabilities for the period represents the deferred tax provision or benefit for the period. Effects of changes in enacted tax laws in deferred tax assets and liabilities are reflected as an adjustment to the tax provision or benefit in the period of enactment.
The Company follows the provisions of ASC 740, Income Taxes, to account for any uncertainty in income taxes with respect to the accounting for all tax positions taken (or expected to be taken) on any income tax return. This guidance applies to all open tax periods in all tax jurisdictions in which the Company is required to file an income tax return. Under U.S. GAAP, in order to recognize an uncertain tax benefit, the taxpayer must be more likely than not certain of sustaining the position, and the measurement of the benefit is calculated as the largest amount that is more likely than not to be realized upon resolution of the position. Interest and penalties, if any, would be recorded within tax expense.
Foreign Currency Translation and Foreign Currency Transactions
Adjustments resulting from translating foreign functional currency financial statements into U.S. Dollars are included in the foreign currency translation adjustment, a component of accumulated other comprehensive loss.
The Company has assets and liabilities, including receivables and payables, which are denominated in currencies other than their functional currency. These balance sheet items are subject to re-measurement, the impact of which is recorded in foreign currency exchange gain and loss, within the condensed consolidated statement of operations and comprehensive loss.
15

Loss Per Share
Basic loss per share includes no dilution and is computed by dividing loss available to common stockholders by the weighted average number of common shares outstanding for the period. Potentially dilutive common shares consist of shares issuable from stock options and unvested RSUs. Potentially dilutive common shares would also include common shares that would be outstanding if the Notes at the balance sheet date were converted. Diluted earnings are not presented when the effect of adding such additional common shares is antidilutive.
Comprehensive Loss
In addition to net loss, comprehensive loss includes all changes in equity during a period, except those resulting from investments by and distributions to owners. The Company holds investments classified as debt securities available-for-sale and records the change in fair market value as a component of comprehensive loss. The Company also has adjustments resulting from translating foreign functional currency financial statements into U.S. Dollars which is included as a component of comprehensive loss.
NOTE 2. RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS
Standards that were recently adopted
In August 2018, the Financial Accounting Standards Board (“FASB”) issued ASU 2018-13, Fair Value Measurement (Topic 820); Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement. ASU 2018-13 modifies, among other things, the disclosures required for Level 3 fair value measurements, including the range and weighted average of significant unobservable inputs. The guidance removes, among other things, the disclosure requirement to disclose transfers between Levels 1 and 2. Level 3 fair value measurement disclosures should be applied prospectively while all other amendments should be applied retrospectively. The Company adopted ASU 2018-13 on January 1, 2020, which had no impact to our condensed consolidated financial statements as the Company did not carry Level 3 fair value items upon implementing this ASU on January 1, 2020.
In June 2016, the FASB issued ASU 2016-13, Financial Instruments-Credit Losses (Topic 326); Measurement of Credit Losses on Financial Instruments. In November 2018, ASU 2018-19 was issued which amended the standard to clarify that receivables arising from operating leases are within the scope of lease accounting standards. Further, the FASB issued ASU 2019-04, 2019-05, 2019-10, ASU 2019-11, 2020-02 and 2020-03 to provide additional guidance on the credit losses standard. ASU 2016-13 amends the guidance on measuring credit losses on financial assets (including trade accounts receivable and available for sale debt securities) held at amortized cost. Previously, an “incurred loss” methodology was used for recognizing credit losses which delays recognition until it is probable a loss has been incurred. This amendment requires assets valued at amortized cost to be presented at the net amount expected to be collected using an allowance for credit losses. Reversal of credit losses on available for sale debt securities are now recorded in current period net income. The Company adopted ASU 2016-13 on January 1, 2020. We adopted this standard using a modified-retrospective approach, and recorded a $0.1 million cumulative-effect adjustment to the opening balance of accumulated deficit in connection with the adoption. This adjustment was recorded to establish an allowance for trade account receivables and investment in leases. No cumulative-effect adjustment was recorded for unrealized losses on debt securities available-for-sale as the issuers of such securities held by us were of high credit quality. As a result, the condensed consolidated financial statements for the current periods are presented under the new standard, while the comparative prior year period is not adjusted and continues to be reported in accordance with our historical accounting policy.
Standards not yet adopted
In January 2020, the FASB issued ASU 2020-01, Investments-Equity Securities (Topic 321), Investments-Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815), Clarifying the Interactions between Topic 321, Topic 323, and Topic 815 (a consensus of the FASB Emerging Issues Task Force). ASU 2020-01 clarifies the interaction of the accounting for equity securities under Topic 321, the accounting for the equity method investments in Topic 323 and the accounting for certain forward contracts and purchased options in Topic 815. This ASU is effective for us on January 1, 2021, with early adoption permitted. We are currently assessing the
16

impact this will have on our condensed consolidated financial statements.
In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740); Simplifying the Accounting for Income Taxes. ASU 2019-12 reduces complexity in the accounting standard. This ASU is effective for us on January 1, 2021, with early adoption permitted. We are currently assessing the impact this will have on our condensed consolidated financial statements.
NOTE 3. CONCENTRATION OF CREDIT RISK
Financial instruments that potentially subject the Company to concentrations of credit risk consist primarily of cash equivalents, short-term investments and accounts receivable, including receivables from major customers.
The Company has financial institutions for banking operations that hold 10% or more of the Company’s cash and cash equivalents. As of June 30, 2020, three of the Company's financial institutions held 59%, 18% and 12% of the Company’s cash and cash equivalents, respectively. As of December 31, 2019, two of the Company's financial institutions held 73% and 18% of the Company’s cash and cash equivalents, respectively.
The Company grants credit to domestic and international customers. Exposure to losses on accounts receivable is principally dependent on each client's financial position. None of the Company's customers accounted for 10% or more of the net accounts receivable balance as of June 30, 2020. The Company had one customer that accounted for 11% of the Company’s net accounts receivable balance as of December 31, 2019.
Customers who represented 10% or more of the Company’s total revenue during the three and six months ended June 30, 2020 and 2019 were as follows:

| Three Months Ended June 30, |  |  | Six Months Ended June 30, |
| 2020 | 2019 |  | 2020 | 2019
Customer A | 10% | * |  | * | *
Customer B | * | 13% |  | * | *
Customer C | * | 11% |  | * | *
Customer D | * | * |  | * | 10%

* Less than 10% for the period indicated
17

NOTE 4. FAIR VALUE OF FINANCIAL INSTRUMENTS
The following tables represent the financial instruments measured at fair value on a recurring basis in the financial statements of the Company and the valuation approach applied to each class of financial instruments at June 30, 2020 and December 31, 2019 (in thousands):

| June 30, 2020 |  |  |
| Quoted Prices in Active Markets for Identical Assets (Level 1) | Significant Other Observable Inputs (Level 2) | Significant Unobservable Inputs (Level 3) | Total
Assets: |  |  |  |
Cash and cash equivalents: |  |  |  |
Money market funds | $ | 28,348 |  | $ | — |  | $ | — |  | $ | 28,348 |
Total cash and cash equivalents | 28,348 |  | — |  | — |  | 28,348 |
Equity investments: |  |  |  |
Mutual funds | 160 |  | — |  | — |  | 160 |
Total equity investments | 160 |  | — |  | — |  | 160 |
Debt securities available-for-sale: |  |  |  |
Certificates of deposit | — |  | 4,961 |  | — |  | 4,961 |
U.S. Treasury securities | 19,193 |  | — |  | — |  | 19,193 |
U.S. Agency securities | — |  | 2,510 |  | — |  | 2,510 |
Corporate notes and bonds | — |  | 14,502 |  | — |  | 14,502 |
Debt securities available-for-sale | 19,193 |  | 21,973 |  | — |  | 41,166 |
Total assets measured at fair value | $ | 47,701 |  | $ | 21,973 |  | $ | — |  | $ | 69,674 |

| December 31, 2019 |  |  |
| Quoted Prices in Active Markets for Identical Assets (Level 1) | Significant Other Observable Inputs (Level 2) | Significant Unobservable Inputs (Level 3) | Total
Assets: |  |  |  |
Cash and cash equivalents: |  |  |  |
Money market funds | $ | 43,745 |  | $ | — |  | $ | — |  | $ | 43,745 |
Commercial paper | — |  | 1,993 |  | — |  | 1,993 |
Corporate notes and bonds | — |  | 1,006 |  | — |  | 1,006 |
Total cash and cash equivalents | 43,745 |  | 2,999 |  | — |  | 46,744 |
Debt securities available-for-sale: |  |  |  |
Certificates of deposit | — |  | 5,663 |  | — |  | 5,663 |
U.S. Treasury securities | 12,579 |  | — |  | — |  | 12,579 |
U.S. Agency securities | — |  | 3,998 |  | — |  | 3,998 |
Commercial paper | — |  | 2,491 |  | — |  | 2,491 |
Corporate notes and bonds | — |  | 22,706 |  | — |  | 22,706 |
Debt securities available-for-sale | 12,579 |  | 34,858 |  | — |  | 47,437 |
Total assets measured at fair value | $ | 56,324 |  | $ | 37,857 |  | $ | — |  | $ | 94,181 |

Highly liquid investments with an original maturity of three months or less at time of purchase are included in cash and cash equivalents on the condensed consolidated balance sheet.
18

Level 1 assets are priced using quoted prices in active markets for identical assets which include money market funds, U.S. Treasury securities and mutual funds as these specific assets are liquid.
Level 2 available-for-sale securities are priced using quoted market prices for similar instruments or nonbinding market prices that are corroborated by observable market data. The Company uses inputs such as actual trade data, benchmark yields, broker/dealer quotes, and other similar data, which are obtained from quoted market prices, independent pricing vendors, or other sources, to determine the ultimate fair value of these assets and liabilities. The Company uses such pricing data as the primary input to make its assessments and determinations as to the ultimate valuation of its investment portfolio and has not made, during the periods presented, any material adjustments to such inputs.
In 2018, the Company issued the Notes, for total proceeds of $171.5 million, as described in Note 11, Convertible Notes. At June 30, 2020 and December 31, 2019, the fair value of the Notes were $122.8 million and $133.8 million, respectively. The fair value of the Notes is highly correlated to the Company’s stock price and as a result, significant changes to the Company’s stock price will have a significant impact on the calculated fair value. The fair value of the Notes are classified as Level 2 within the fair value hierarchy. See Note 11, Convertible Notes for further detail on the Company’s convertible notes.
On April 14, 2020, the Company entered into the PPP Note evidencing a loan in the amount of $4.8 million, which approximates the fair value due to the short-term nature of the instrument. The estimated fair value of the Company’s long-term debt represents a Level 3 measurement, as the Loan is privately held with no public market. See Note 10, Long-Term Debt for further detail on the PPP Note.
NOTE 5. INVESTMENTS
The following tables summarize the Company’s debt securities available-for-sale investments at June 30, 2020 and December 31, 2019 (in thousands):

| June 30, 2020 |  |  |
| Amortized Cost | Gross Unrealized Gains | Gross Unrealized Losses | Fair Value
Certificates of deposit | $ | 4,925 |  | $ | 36 |  | $ | — |  | $ | 4,961 |
U.S. Treasury securities | 19,086 |  | 107 |  | — |  | 19,193 |
U.S. Agency securities | 2,510 |  | — |  | — |  | 2,510 |
Corporate notes and bonds | 14,444 |  | 58 |  | — |  | 14,502 |
Total | $ | 40,965 |  | $ | 201 |  | $ | — |  | $ | 41,166 |

| December 31, 2019 |  |  |
| Amortized Cost | Gross Unrealized Gains | Gross Unrealized Losses | Fair Value
Certificates of deposit | $ | 5,646 |  | $ | 17 |  | $ | — |  | $ | 5,663 |
U.S. Treasury securities | 12,564 |  | 16 |  | (1) |  | 12,579 |
U.S. Agency securities | 4,002 |  | — |  | (4) |  | 3,998 |
Commercial paper | 2,492 |  | — |  | (1) |  | 2,491 |
Corporate notes and bonds | 22,711 |  | 6 |  | (11) |  | 22,706 |
Total | $ | 47,415 |  | $ | 39 |  | $ | (17) |  | $ | 47,437 |

19

The following table summarizes the maturities of the Company’s debt securities available-for-sale investments at June 30, 2020 and December 31, 2019 (in thousands):

| June 30, 2020 |  | December 31, 2019 |
| Amortized Cost | Fair Value | Amortized Cost | Fair Value
Due in less than 1 year | $ | 40,718 |  | $ | 40,915 |  | $ | 43,627 |  | $ | 43,650 |
Due in 1-3 years | 247 |  | 251 |  | 3,788 |  | 3,787 |
| $ | 40,965 |  | $ | 41,166 |  | $ | 47,415 |  | $ | 47,437 |

Proceeds from sales of debt securities available-for-sale (including principal paydowns) for the three months ended June 30, 2020 and 2019 were $0 and $4.4 million, respectively, and for the six months ended June 30, 2020 and 2019 were $0 and $13.4 million, respectively. The Company determines gains and losses of marketable securities based on specific identification of the securities sold. There were no material realized gains or losses from debt securities available-for-sale for the three and six months ended June 30, 2020 and 2019. No material balances were reclassified out of accumulated other comprehensive loss for the three and six months ended June 30, 2020 and 2019.
As of June 30, 2020, there were no holdings of debt securities available-for-sale of any one issuer, other than the U.S. government, in an amount greater than 10%. As of June 30, 2020 there were no debt securities available-for-sale in an unrealized loss position.
As of June 30, 2020 the Company carried debt securities available-for-sale that were certificates of deposits, which were not covered by a rating agency or the credit rating was below the Company's minimum credit rating. As of June 30, 2020 all of the Company's certificate deposits were below the FDIC's insurance limit of $250 thousand per depositor which mitigated the Companies investment risk. All other debt securities available-for-sale had a credit rating of A- or better as of June 30, 2020.
Equity securities are comprised of investments in mutual funds. The fair value of equity securities at June 30, 2020 was $0.2 million. There were no material unrealized gains or losses on equity securities recorded in income for the three and six months ended June 30, 2020. These unrealized gains or losses are recorded as a component of other income (expense), net. There were no realized gains or losses from equity securities for the three and six months ended June 30, 2020.
NOTE 6. INVENTORY
Inventories consisted of the following at June 30, 2020 and December 31, 2019 (in thousands):

| June 30, | December 31,
| 2020 | 2019
Raw materials | $ | 5,500 |  | $ | 4,854 |
Work in process | 1,237 |  | 1,561 |
Finished goods | 1,986 |  | 1,644 |
| $ | 8,723 |  | $ | 8,059 |

20

NOTE 7. PROPERTY AND EQUIPMENT
Property and equipment consisted of the following at June 30, 2020 and December 31, 2019 (in thousands):

| June 30, | December 31,
| 2020 | 2019
Computer equipment | $ | 2,595 |  | $ | 2,477 |
Technical equipment | 3,983 |  | 3,681 |
Facilities | 3,687 |  | 3,883 |
Instruments | 8,100 |  | 7,491 |
Capital projects in progress | 336 |  | 238 |
Total property and equipment | $ | 18,701 |  | $ | 17,770 |
Accumulated depreciation | (10,697) |  | (9,865) |
Property and equipment, net | $ | 8,004 |  | $ | 7,905 |

Depreciation expense for the three months ended June 30, 2020 and 2019 was $0.6 million and $0.5 million, respectively, and for the six months ended June 30, 2020 and 2019 was $1.2 million and $1.1 million, respectively.
Gross assets under operating leases where the Company is the lessor at June 30, 2020 and December 31, 2019 is $5.5 million and $4.6 million, respectively. The underlying accumulated depreciation under operating leases where the Company is the lessor at June 30, 2020 and December 31, 2019 is $1.3 million and $0.8 million, respectively.
NOTE 8. LICENSE AGREEMENTS AND GRANTS
National Institute of Health Grant
In February 2015, the National Institute of Health awarded Denver Health and the Company a five-year, $5.0 million grant to develop a fast and reliable identification and categorical susceptibility test for carbepenem-resistant Enterobacteriaceae directly from whole blood. The grant is paid to the Company incrementally through sub-awards. The cumulative amount awarded to date under these sub-awards is $1.5 million. The amount invoiced for each of the three months ended June 30, 2020 and 2019 was $0.1 million, and for the six months ended June 30, 2020 and 2019 was $0.1 million and $0.2 million, respectively. Subsequent to the original term of the grant the National Institute of Health has provided incremental annual extensions that have allowed the Company to provide additional services.
NOTE 9. DEFERRED REVENUE AND REMAINING PERFORMANCE OBLIGATIONS
Deferred revenue consists of amounts received for products or services not yet delivered or earned. If we anticipate revenue will not be earned within the following twelve months, the amount is reported as other non-current liabilities. A summary of the balances as of June 30, 2020 and December 31, 2019 follows (in thousands):

| June 30, | December 31,
| 2020 | 2019
Products and services not yet delivered | $ | 232 |  | $ | 271 |

We recognized $0.1 million and $0.2 million of revenues that were included in the beginning contract liabilities balances during the three and six months ended June 30, 2020, respectively. No material revenues were recognized that were included in the beginning contract liabilities balances during the three and six months ended June 30, 2019. No material amount of revenue recognized during the period was from performance obligations satisfied in prior periods.
21

Transaction Price Allocated to Remaining Performance Obligations
As of June 30, 2020, $4.5 million of revenue is expected to be recognized from remaining performance obligations. This balance primarily relates to product shipments for reagent rental, sales-type lease agreements. The agreements have between two and four year terms and revenue is recognized as product is shipped, typically on a straight-line basis. The remaining balance relates to executed service contracts that begin as warranty periods expire. These service contracts typically provide for four-year terms and revenue is recognized on a straight-line basis.
The Company elects not to disclose the value of unsatisfied performance obligations for (i) contracts with an expected length of one year or less and (ii) contracts for which we recognize revenue at the amount to which we have the right to invoice for services performed.
NOTE 10. LONG-TERM DEBT
On April 14, 2020, the Company entered into the PPP Note evidencing an unsecured loan in the amount of $4.8 million made to the Company under the PPP. The PPP was established under the CARES Act and is administered by the SBA.
The PPP Note matures on April 14, 2022 and bears interest at a rate of 1% per annum. Beginning November 14, 2020, the Company is required to make 18 monthly payments of principal and interest in the amount of $0.3 million. The PPP Note may be prepaid by the Company at any time prior to maturity with no prepayment penalties. The proceeds from the PPP Note may only be used for payroll costs (including benefits), interest on mortgage obligations, rent, utilities and interest on certain other debt obligations.
The PPP Note contains customary events of default relating to, among other things, payment defaults, making materially false and misleading representations to the lender or breaching the terms of the PPP Note documents. The occurrence of an event of default will result in an increase in the interest rate to 18% per annum and provides the lender with customary remedies, including the right to require immediate payment of all amounts owed under the PPP Note.
Pursuant to the terms of the CARES Act and the PPP, the Company may apply to the lender for forgiveness for the amount due on the PPP Note. The amount eligible for forgiveness is based on the amount of PPP Note proceeds used by the Company (during the 24 week period after the lender makes the first disbursement of PPP Note proceeds) for the payment of certain covered costs, including payroll costs (including benefits), rent and utilities, subject to certain limitations and reductions in accordance with the CARES Act and the PPP. No assurance can be given that the Company will obtain forgiveness of the PPP Note in whole or in part. As of June 30, 2020 the Company had not applied for forgiveness.
The following presents maturities of future principal obligations under the PPP Note as of June 30, 2020 (in thousands):

Remainder of 2020 | $ | 517 |
2021 | 3,200 |
2022 | 1,074 |
2023 | — |
2024 | — |
Thereafter | — |
Total | $ | 4,791 |

22

NOTE 11. CONVERTIBLE NOTES
On March 27, 2018, the Company issued $150.0 million aggregate principal amount of 2.50% Senior Convertible Notes due 2023. In connection with the offering of the Notes, the Company granted the initial purchasers of the Notes a 13-day option to purchase up to an additional $22.5 million aggregate principal amount of the Notes on the same terms and conditions. On April 4, 2018, the option was partially exercised, which resulted in $21.5 million of additional proceeds, for total proceeds of $171.5 million. The Notes are the Company's senior unsecured obligations and mature on March 15, 2023 (the “Maturity Date”), unless earlier repurchased or converted into shares of common stock under certain circumstances described below. The Notes are convertible into shares of the Company’s common stock, can be repurchased for cash, or a combination thereof, at the Company’s election, at an initial conversion rate of 32.3428 shares of common stock per $1,000 principal amount of the Notes, which is equivalent to an initial conversion price of approximately $30.92 per share of common stock, subject to adjustment. The Company pays interest on the Notes semi-annually in arrears on March 15 and September 15 of each year.
The $171.5 million of proceeds received from the issuance of the Notes were allocated between long-term debt (the “liability component”) of $116.6 million and contributed capital (the “equity component”) of $54.9 million. The fair value of the liability component was measured using rates determined for similar debt instruments without a conversion feature. The carrying amount of the equity component, representing the conversion option, was determined by deducting the fair value of the liability component from the aggregate face value of the Notes. The liability component will be accreted up to the face value of the Notes of $171.5 million, which will result in additional non-cash interest expense being recognized through the Maturity Date. The equity component will not be remeasured as long as it continues to meet the conditions for equity classification.
The Company incurred approximately $5.0 million of issuance costs related to the issuance of the Notes, of which $3.4 million and $1.6 million were recorded to long-term debt and contributed capital, respectively. The $3.4 million of issuance costs recorded as long-term debt on the condensed consolidated balance sheet are being amortized over the five-year contractual term of the Notes using the effective interest method. The effective interest rate on the Notes, including accretion of the Notes to par and debt issuance cost amortization, is 11.52%.
The Notes include customary terms and covenants, including certain events of default upon which the Notes may be due and payable immediately. Holders have the option to convert the Notes in multiples of $1,000 principal amount at any time prior to December 15, 2022, but only in the following circumstances:
•if the Company’s stock price exceeds 130% of the conversion price for 20 of the last 30 trading days of any calendar quarter after June 30, 2018;
•during the 5 business day period after any 5 consecutive trading day period in which the Notes’ trading price is less than 98% of the product of the common stock price times the conversion rate; or
•the occurrence of certain corporate events, such as a change of control, merger or liquidation.
At any time on or after December 15, 2022, a holder may convert its Notes in multiples of $1,000 principal amount. Holders of the Notes who convert their Notes in connection with a make-whole fundamental change (as defined in the Indenture pursuant to which the Notes were issued) are, under certain circumstances, entitled to an increase in the conversion rate. In addition, in the event of a fundamental change or event of default prior to the Maturity Date, holders will, subject to certain conditions, have the right, at their option, to require the Company to repurchase for cash all or part of the Notes at a repurchase price equal to 100% of the principal amount of the Notes to be repurchased, plus accrued and unpaid interest up to, but excluding, the repurchase date.
23

The Notes at June 30, 2020 and December 31, 2019 consisted of the following (in thousands):

| June 30, | December 31,
| 2020 | 2019
Outstanding principal | $ | 171,500 |  | $ | 171,500 |
Unamortized debt discount | (33,932) |  | (39,042) |
Unamortized debt issuance | (2,099) |  | (2,415) |
Net carrying amount of the liability component | $ | 135,469 |  | $ | 130,043 |

Interest expense for the three and six months ended June 30, 2020 and 2019 were as follows (in thousands):

| Three Months Ended June 30, |  |  | Six Months Ended June 30, |
| 2020 | 2019 |  | 2020 | 2019
Contractual coupon interest | $ | 1,072 |  | $ | 1,072 |  |  | $ | 2,144 |  | $ | 2,144 |
Amortization of the debt discount | 2,591 |  | 2,313 |  |  | 5,109 |  | 4,561 |
Amortization of debt issuance costs | 160 |  | 143 |  |  | 316 |  | 282 |
Total interest expense on convertible notes | $ | 3,823 |  | $ | 3,528 |  |  | $ | 7,569 |  | $ | 6,987 |

As of June 30, 2020 and December 31, 2019, no Notes were convertible pursuant to their terms.
In connection with the Notes issuance, the Company entered into a prepaid forward stock repurchase transaction (“Prepaid Forward”) with a financial institution (“Forward Counterparty”). Pursuant to the Prepaid Forward, the Company used approximately $45.1 million of the net proceeds from its issuance of the Notes to fund the Prepaid Forward. The aggregate number of shares of the Company’s common stock underlying the Prepaid Forward was approximately 1,858,500. The expiration date for the Prepaid Forward is March 15, 2023, although it may be settled earlier in whole or in part. Upon settlement of the Prepaid Forward, at expiration or upon any early settlement, the Forward Counterparty will deliver to the Company the number of shares of common stock underlying the Prepaid Forward or the portion thereof being settled early. The shares purchased under the Prepaid Forward are treated as treasury stock and not outstanding for purposes of the calculation of basic and diluted earnings per share, but will remain outstanding for corporate law purposes, including for purposes of any future stockholders’ votes, until the Forward Counterparty delivers the shares underlying the Prepaid Forward to the Company. The Company’s Prepaid Forward hedge transaction exposes the Company to credit risk to the extent that its counterparty may be unable to meet the terms of the transaction. The Company mitigates this risk by limiting its counterparty to a major financial institution.
24

NOTE 12. EARNINGS PER SHARE
Basic net loss per common share was determined by dividing net loss applicable to common stockholders by the weighted average common shares outstanding during the period. Basic and diluted net loss per share are the same because all outstanding common stock equivalents have been excluded, as they are anti-dilutive due to the Company’s losses.
The following potentially issuable common shares were not included in the computation of diluted net loss per share because they would have an anti-dilutive effect for each of the three and six months ended June 30, 2020 and 2019 (in thousands):

| Three Months Ended June 30, |  |  | Six Months Ended June 30, |
| 2020 | 2019 |  | 2020 | 2019
Shares issuable upon the release of restricted stock units | 704 |  | 25 |  |  | 704 |  | 25 |
Shares issuable upon exercise of stock options | 9,773 |  | 9,102 |  |  | 9,773 |  | 9,102 |
| 10,477 |  | 9,127 |  |  | 10,477 |  | 9,127 |

Potentially dilutive common shares would also include common shares that would be outstanding if Notes convertible at the balance sheet date were converted. As discussed in Note 11, Convertible Notes, the Company issued $171.5 million of Notes due 2023. The Notes are convertible into shares of the Company’s common stock, can be repurchased for cash, or a combination thereof, at the Company’s election, at an initial conversion rate of 32.3428 shares of common stock per $1,000 principal amount of the Notes. As of June 30, 2020, no Notes were convertible pursuant to their terms. The number of shares issuable upon conversion of the Notes is 5.5 million shares.
In connection with the Notes, the Company entered into a prepaid forward stock repurchase transaction. The aggregate number of shares of the Company’s common stock underlying the Prepaid Forward was approximately 1,858,500. The shares purchased under the Prepaid Forward are treated as treasury stock and not outstanding for purposes of the calculation of basic and diluted earnings per share, but will remain outstanding for corporate law purposes, including for purposes of any future stockholders’ votes, until the Forward Counterparty delivers the shares underlying the Prepaid Forward to the Company.
NOTE 13. EMPLOYEE EQUITY-BASED COMPENSATION
The following table summarizes option activity under all plans for the six months ended June 30, 2020:

| Number of Shares | Weighted Average Exercise Price per Share
Options Outstanding January 1, 2020 | 10,132,562 |  | $ | 12.28 |
Granted | 1,553,314 |  | 8.01 |
Forfeited | (303,023) |  | 14.96 |
Exercised | (1,490,048) |  | 2.03 |
Expired | (119,562) |  | 19.38 |
Options Outstanding June 30, 2020 | 9,773,243 |  | $ | 12.99 |

25

The table below summarizes the resulting weighted average inputs used to calculate the estimated fair value of options awarded for the three months ended June 30, 2020 and 2019:

| Three Months Ended June 30, |
| 2020 | 2019
Expected term (in years) | 5.83 | 5.65
Volatility | 60 | % | 58 | %
Expected dividends | — |  | — |
Risk free interest rates | 0.39 | % | 2.38 | %
Weighted average fair value | $ | 4.72 |  | $ | 11.08 |

The following table shows summary information for outstanding options and options that are exercisable (vested) as of June 30, 2020:

| Options Outstanding | Options Exercisable
Number of options | 9,773,243 |  | 5,427,723 |
Weighted average remaining contractual term (in years) | 6.27 | 4.30
Weighted average exercise price | $ | 12.99 |  | $ | 11.80 |
Weighted average fair value | $ | 8.19 |  | $ | 7.69 |
Aggregate intrinsic value (in thousands) | $ | 44,119 |  | $ | 32,341 |

The following table summarizes RSU and restricted stock award activity for the six months ended June 30, 2020:

| Number of Shares | Weighted Average Grant Date Fair Value per Share
Outstanding January 1, 2020 | 14,332 |  | $ | 16.66 |
Granted | 739,217 |  | 11.30 |
Forfeited | (21,719) |  | 9.01 |
Vested/released | (28,141) |  | 9.79 |
Outstanding June 30, 2020 | 703,689 |  | $ | 11.54 |

The table below summarizes equity-based compensation expense for the three and six months ended June 30, 2020 and 2019 (in thousands):

| Three Months Ended June 30, |  |  | Six Months Ended June 30, |
| 2020 | 2019 |  | 2020 | 2019
Cost of sales | $ | 59 |  | $ | 52 |  |  | $ | 130 |  | $ | 107 |
Research and development | 335 |  | 802 |  |  | 1,458 |  | 2,329 |
Sales, general and administrative | 3,022 |  | 2,027 |  |  | 6,027 |  | 3,842 |
| $ | 3,416 |  | $ | 2,881 |  |  | $ | 7,615 |  | $ | 6,278 |

26

The table below summarizes share-based compensation cost capitalized to inventory or inventory transferred to property and equipment (also referred to as instruments) for the three and six months ended June 30, 2020 and 2019 (in thousands):

| Three Months Ended June 30, |  |  | Six Months Ended June 30, |
| 2020 | 2019 |  | 2020 | 2019
Cost capitalized to inventory | $ | 28 |  | $ | 96 |  |  | $ | 138 |  | $ | 240 |

As of June 30, 2020, unrecognized equity-based compensation expense related to unvested stock options and unvested RSUs was $20.5 million and $4.6 million, respectively. This is expected to be recognized over the years 2020 through 2025.
Included in the above-noted stock options outstanding and stock compensation expense are performance-based stock options which vest only upon the achievement of certain targets. Performance-based stock options are generally granted at-the-money, contingently vest over a period of 1 to 2 years, depending on the nature of the performance goal, and have contractual lives of 10 years. These options were valued in the same manner as the time-based options, with the assumption that performance goals will be achieved. The inputs for expected volatility, expected dividends, and risk-free rate used in estimating those options’ fair value are the same as the time-based options issued under the plan. The expected term for performance-based stock options is 5 to 7 years. However, the Company only recognizes stock compensation expense to the extent that the targets are determined to be probable of being achieved, which triggers the vesting of the performance options.
In August 2018, the Company granted 225,000 performance-based stock options. As of June 30, 2020 the performance obligations had been met for 75,000 options which became exercisable, and the remaining 150,000 options were forfeited for the performance targets not being achieved. No stock compensation expense for the forfeited performance-based stock options was recognized. The stock compensation expense for the vested options was recorded in prior periods.
In April 2020, the Company granted another 105,000 performance-based stock options. As of June 30, 2020 the performance obligations were not yet probable and the entire balance was outstanding. None of these options have been forfeited and no stock compensation expense was recorded as of June 30, 2020.
The table below summarizes share-based compensation cost in connection with performance-based stock options for the six months ended June 30, 2020 and 2019 (in thousands):

| Six Months Ended June 30, |
| 2020 | 2019
Performance-based stock option expense | $ | — |  | $ | 107 |

Included in the above-noted RSU and restricted stock award outstanding amount are performance-based RSU's which vest only upon the achievement of certain targets. Performance-based RSU's contingently vest over a period of 1 to 3 years, depending on the nature of the performance goal, and have contractual lives of 10 years. These units were valued in the same manner as other RSUs, based on the published closing market price on the day before the grant date. However, the Company only recognizes stock compensation expense to the extent that the targets are determined to be probable of being achieved, which triggers the vesting of the performance options.
During the six months ended June 30, 2020, the Company granted 351,396 performance-based RSU's, with 337,343 performance-based RSU's being outstanding as of June 30, 2020. None of the performance goals had become probable of being achieved, and no expense was recorded at June 30, 2020.
27

NOTE 14. INCOME TAXES
For the six months ended June 30, 2020, the Company did not carry an income tax provision amount as the Company does not recognize tax benefits from current year tax losses in the U.S. and other foreign jurisdictions. The Company’s tax expense for the three and six months ended June 30, 2020 differs from the tax expense computed by applying the U.S. statutory tax rate to its year-to-date pre-tax loss of $40.5 million, as no tax benefits were recorded for tax losses generated in the U.S. and other foreign jurisdictions. At June 30, 2020, the Company had deferred tax assets primarily related to U.S. federal and state tax loss carryforwards and a deferred tax liability related to amortization of the Notes. The Company provided a valuation allowance against its net deferred tax assets as future realization of such assets is not more likely than not to occur.
On March 27, 2020, the U.S. enacted the CARES Act. The CARES Act is an emergency economic stimulus package that includes spending and tax breaks to strengthen the U.S. economy and fund a nationwide effort to curtail the effect of COVID-19. While the CARES Act provides sweeping tax changes in response to the COVID-19 pandemic, some of the more significant provisions include removal of certain limitations on utilization of net operating losses, increasing the loss carryback period for certain losses to five years, and increasing the ability to deduct interest expense, as well as amending certain provisions of the previously enacted Tax Cuts and Jobs Act. Management does not expect the CARES Act to have a material impact on the Company’s income tax position for financial reporting purposes. The Company will continue its assessment of the CARES Act on its financial statements, as changes in tax legislation and further guidance for the CARES Act become available in the subsequent quarters.
The Company accounts for uncertain tax positions pursuant to the recognition and measurement criteria under ASC 740, Income Taxes. For the three and six months ended June 30, 2020, we did not note any significant changes to our uncertain tax positions. We do not anticipate significant changes to uncertain tax positions within the next 12 months.
NOTE 15. COMMITMENTS
Clinical Trial & Study Agreements
The Company has entered into master agreements with clinical trial and study sites in which we typically pay a set amount for start-up costs and then pay for work performed. These agreements typically indemnify the clinical trial sites from any and all losses arising from third party claims as a result of the Company's negligence, willful misconduct or misrepresentation. The expenses for start-up costs and work performed for these trials and studies is recorded as research and development or sales, general and administrative expenses on the Company's condensed consolidated statements of operations and comprehensive loss. No commitments were recorded in connection with indemnifying these sites during the three and six months ended June 30, 2020 and 2019.
NOTE 16. LEASES
The following presents supplemental information related to our leases in which we are the lessee for the three and six months ended June 30, 2020 and 2019 (in thousands):

| Three Months Ended June 30, |  |  | Six Months Ended June 30, |
| 2020 | 2019 |  | 2020 | 2019
Cash paid for amounts included in lease liabilities |  |  |  |  |
Operating cash flows from operating leases | $ | 183 |  | $ | 83 |  |  | $ | 366 |  | $ | 165 |
ROU assets obtained in exchange for lease obligations |  |  |  |  |
Operating leases | $ | — |  | $ | — |  |  | $ | 17 |  | $ | — |
Lease Cost |  |  |  |  |
Operating leases | $ | 248 |  | $ | 83 |  |  | $ | 513 |  | $ | 165 |
Short-term leases | $ | 6 |  | $ | 299 |  |  | $ | 35 |  | $ | 590 |

28

The weighted average remaining lease term on our operating leases is 4.9 years. The weighted average discount rate on those leases is 7%.
The following presents maturities of operating lease liabilities in which we are the lessee as of June 30, 2020 (in thousands):

Remainder of 2020 | $ | 351 |
2021 | 753 |
2022 | 875 |
2023 | 968 |
2024 | 1,055 |
Thereafter | 609 |
Total lease payments | 4,611 |
Less imputed interest | (797) |
| $ | 3,814 |

The net investment in sales-type leases, where we are the lessor, is a component of other current assets and other non-current assets in our condensed consolidated balance sheet. As of June 30, 2020, the total net investment in these leases was $1.2 million. The following presents maturities of lease receivables under sales-type leases as of June 30, 2020 (in thousands):

Remainder of 2020 | $ | 234 |
2021 | 416 |
2022 | 359 |
2023 | 101 |
2024 | 47 |
Thereafter | 43 |
Total undiscounted cash flows | 1,200 |
Less imputed interest | — |
Present value of lease payments | $ | 1,200 |

NOTE 17. INDUSTRY, GEOGRAPHIC AND REVENUE DISAGGREGATION
The Company operates as one operating segment. Sales to customers outside the U.S. represented 6% and 24% for the three months ended June 30, 2020 and 2019, respectively, and 8% and 28% for the six months ended June 30, 2020 and 2019, respectively.
As of June 30, 2020 and December 31, 2019, balances due from foreign customers, in U.S. dollars, were $1.3 million and $2.1 million, respectively.
The following presents total net sales by geographic territory for the three and six months ended June 30, 2020 and 2019 (in thousands):

| Three Months Ended June 30, |  |  | Six Months Ended June 30, |
| 2020 | 2019 |  | 2020 | 2019
Domestic | $ | 2,003 |  | $ | 1,380 |  |  | $ | 4,091 |  | $ | 2,551 |
Foreign | 122 |  | 426 |  |  | 377 |  | 1,006 |
| $ | 2,125 |  | $ | 1,806 |  |  | $ | 4,468 |  | $ | 3,557 |

29

The following presents total net sales by line of business for the three and six months ended June 30, 2020 and 2019 (in thousands):

| Three Months Ended June 30, |  |  | Six Months Ended June 30, |
| 2020 | 2019 |  | 2020 | 2019
Accelerate Pheno revenue | $ | 2,093 |  | $ | 1,777 |  |  | $ | 4,398 |  | $ | 3,483 |
Other revenue | 32 |  | 29 |  |  | 70 |  | 74 |
| $ | 2,125 |  | $ | 1,806 |  |  | $ | 4,468 |  | $ | 3,557 |

The following presents total net sales by products and services for the three and six months ended June 30, 2020 and 2019 (in thousands):

| Three Months Ended June 30, |  |  | Six Months Ended June 30, |
| 2020 | 2019 |  | 2020 | 2019
Products | $ | 1,937 |  | $ | 1,695 |  |  | $ | 4,079 |  | $ | 3,389 |
Services | 188 |  | 111 |  |  | 389 |  | 168 |
| $ | 2,125 |  | $ | 1,806 |  |  | $ | 4,468 |  | $ | 3,557 |

Lease income included in net sales was $0.3 million and $0.2 million for the three months ended June 30, 2020 and 2019, respectively, and $0.8 million and $0.4 million for the six months ended June 30, 2020 and 2019, respectively, which does not represent revenues recognized from contracts with customers.
The following presents property and equipment, net by geographic territory (in thousands):

| June 30, | December 31,
| 2020 | 2019
Domestic | $ | 7,456 |  | $ | 7,244 |
Foreign | 548 |  | 661 |
| $ | 8,004 |  | $ | 7,905 |

NOTE 18. RELATED PARTY TRANSACTIONS
As discussed in Note 11, Convertible Notes the Company issued Notes in March 2018. As of June 30, 2020 and December 31, 2019 an entity controlled by one member of the Company's board of directors held an aggregate of $42.0 million of the Notes.
On August 20, 2019, the Company and an entity affiliated with then Chief Operating Officer and current Chief Executive Officer of the Company entered into a securities purchase agreement (the “Purchase Agreement”) for the issuance and sale by the Company of an aggregate of 55,586 shares of the Company’s common stock (the “Shares”) in an offering exempt from registration pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended, and Rule 506 promulgated thereunder. The Shares were sold at a purchase price (determined in accordance with Nasdaq rules relating to the “market value” of the shares) of $17.99 per share, which was equal to the consolidated closing bid price reported by Nasdaq immediately preceding the time the Company entered into the Purchase Agreement. The $1.0 million of proceeds were recorded to contributed capital.
30

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations
Introductory Note
Except as otherwise indicated by the context, references in this Quarterly Report on Form 10-Q (this “Form 10-Q”) to the “Company,” “Accelerate,” “we,” “us” or “our” are references to the combined business of Accelerate Diagnostics, Inc. The following Management’s Discussion and Analysis of Financial Condition and Results of Operations (“MD&A”) summarizes the significant factors affecting our results of operations, liquidity, capital resources and contractual obligations. The following discussion and analysis should be read in conjunction with the Company’s unaudited condensed consolidated financial statements and related notes included elsewhere herein.
All amounts in the MD&A have been rounded to the nearest thousand unless otherwise indicated.
Forward-Looking Statements
This Form 10-Q contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the Company intends that such forward-looking statements be subject to the safe harbors created thereby. These forward-looking statements, which can be identified by the use of words such as “may,” “will,” “expect,” “anticipate,” “estimate,” or “continue,” or variations thereon or comparable terminology, include but are not limited to, statements about the plans and objectives of management for future operations, including plans and objectives relating to the products and future performance of the Company; projections of our future financial performance and demand for our products; the anticipated impacts from the COVID-19 pandemic on the Company, including to our business, results of operations, cash flows and financial position, as well as our future responses to the COVID-19 pandemic; and our plans or expectations with relating to our agreement with BioCheck, Inc. (“BioCheck”). In addition, all statements other than statements of historical facts that address activities, events, or developments the Company expects, believes, or anticipates will or may occur in the future, and other such matters, are forward-looking statements.
Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. There can be no assurances that results described in forward-looking statements will be achieved, and actual results could differ materially from those suggested by the forward-looking statements. The forward-looking statements included herein are based on current expectations that involve a number of risks and uncertainties, including the duration and severity of the COVID-19 pandemic and its ultimate effect on our business, results of operations, cash flows and financial position, as well as our ability (or inability) to execute on our plans to respond to the COVID-19 pandemic. Other important factors that could cause our actual results to differ materially from those in our forward-looking statements include those discussed herein, and in other reports filed with the SEC including but not limited to the risks in the section entitled “Risk Factors” in the Company's Annual Report on Form 10-K for the year ended December 31, 2019, the section entitled “Risk Factor” in this Form 10-Q and in the Company's subsequent filings with the SEC. These forward-looking statements are also based on assumptions that the Company will retain key management personnel, the Company will be successful in the commercialization of the Accelerate Pheno® system, the Company will obtain sufficient capital to commercialize the Accelerate Pheno system and continue development of complementary products, the Company will be able to protect its intellectual property, the Company’s ability to respond to technological change, the Company will accurately anticipate market demand for the Company’s products and there will be no material adverse change in the Company’s operations or business. Assumptions relating to the foregoing involve judgments with respect to, among other things, future economic, competitive and market conditions and future business decisions, all of which are difficult or impossible to predict accurately and many of which are beyond the control of the Company. Although the Company believes that the assumptions underlying the forward-looking statements are reasonable, any of the assumptions could prove inaccurate and, therefore, there can be no assurance that the results contemplated in forward-looking statements will be realized. Any forward-looking statements made by us in this Form 10-Q speak only as of the date on which they are made. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
31

Overview
Accelerate Diagnostics, Inc. (“Accelerate”) is an in vitro diagnostics company dedicated to providing solutions that improve patient outcomes and lower healthcare costs through the rapid diagnosis of serious infections. Microbiology laboratories are in need of new tools to address what the U.S. Centers for Disease Control and Prevention (the “CDC”) calls one of the most serious healthcare threats of our time, antibiotic resistance. A significant contributing factor to the rise of resistance is the overuse and misuse of antibiotics, which is exacerbated by a lack of timely diagnostic results. The delay of identification and antibiotic susceptibility results is often due to the reliance by microbiology laboratories on traditional culture-based tests that often take two to three days to complete. Our technology platform is built to address these challenges by delivering significantly faster testing of infectious pathogens in various patient sample types.
Our first system to address these challenges is the Accelerate Pheno system. The Accelerate Pheno system utilizes genotypic technology to identify (“ID”) infectious pathogens and phenotypic technology to conduct antibiotic susceptibility testing (“AST”), which determines whether live bacterial and fungal cells are resistant or susceptible to a particular antimicrobial. The Accelerate PhenoTest® BC Kit, which is the first test kit for the system, provides ID and AST results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. This information is used to rapidly modify antibiotic therapy to lessen side-effects, improve clinical outcomes, and help preserve the useful life of antibiotics.
On June 30, 2015, we declared our conformity to the European In Vitro Diagnostic Directive 98/79/EC and applied a CE Mark to the Accelerate Pheno system and the Accelerate PhenoTest BC Kit for in vitro diagnostic use. On February 23, 2017, the U.S. Food and Drug Administration (“FDA”) granted our de novo request to market our Accelerate Pheno system and Accelerate PhenoTest BC Kit.
In 2017, we began selling the Accelerate Pheno system in hospitals in the U.S., Europe, and the Middle East. Consistent with the Company's “razor” / “razor-blade” business model, revenues to date have principally been generated from the sale of the instruments and the sale of single use consumable test kits.
In 2019, based upon our initial experience selling and implementing the Accelerate Pheno system, we implemented initiatives to improve and refine our commercial execution and to re-engineer our product implementation processes. Improving our commercial and implementation capabilities remains an emphasis going forward, along with geographic expansion and product innovation.
On April 13, 2020 we signed a non-exclusive agreement with BioCheck to sell MS-FAST, a fully-automated chemiluminescence immunoassay analyzer, along with BioCheck’s SARS-CoV-2 tests for the detection of IgG and IgM antibodies (together the “BioCheck COVID-19 Serology System”) in North America, Europe and the Middle East. We will pay BioCheck a pre-defined price for the sale of each BioCheck COVID-19 Serology System device and assay. The BioCheck COVID-19 Serology System has a CE Mark and FDA Emergency Use Authorization approval is pending. The BioCheck COVID-19 Serology System will be the first third-party product sold by Accelerate, the first product sold by Accelerate outside bacterial infections, and will be directed at the rapidly evolving COVID-19 serology market. As such, there are uncertainties regarding market demand, market acceptance, supply constraints, FDA authorization, ramp up expenditures, and other factors impacting market penetration.
COVID-19 Update
In late 2019, a novel strain of coronavirus (COVID-19) was reported to have surfaced in Wuhan, China, which has since spread globally. In March 2020, the World Health Organization declared COVID-19 a global pandemic. Further, the COVID-19 outbreak has resulted in government authorities around the world implementing numerous measures to try to reduce the spread of COVID-19, such as travel bans and restrictions, quarantines, shelter-in-place, stay-at-home or total lock-down (or similar) orders and business limitations and shutdowns. For example, the State of Arizona has implemented several orders promoting physical distancing, limiting certain activities,and restricting the operations of certain businesses, including restaurants, bars, gyms, theaters and water parks. The COVID-19 pandemic and these measures have caused, and are continuing to cause, business slowdowns or shutdowns in affected areas, both regionally and worldwide, which have significantly impacted our business and results of operations.
32

For example, as a result of the pandemic, during March 2020 and throughout the second quarter of 2020, our access to customers to sell and implement the Accelerate Pheno system diminished as hospitals became primarily focused on the COVID-19 pandemic. The limited access to current and potential customers has significantly reduced our ability to complete sales of new Accelerate Pheno systems and to implement previously sold Accelerate Pheno systems, thereby reducing the growth of our consumable test kits. We are uncertain how long these conditions will persist potentially impacting the contracting of new customers and reestablishing a normal cadence on implementations with currently contracted customers.
The reduced sales and implementations caused by the COVID-19 pandemic lowered our expected revenue growth in the second quarter of 2020. Because we believe our reduced revenue growth will persist through 2020, at the end of the second quarter of 2020 we furloughed certain employees and implemented salary reductions for executives and other highly compensated employees. We expect some of the furloughs to be permanent, and others to continue until the end of the year.
As a medical device company, we have not experienced any disruptions to our ability to manufacture our products at our Tucson, Arizona headquarters under the various State of Arizona executive orders relating to the COVID-19 pandemic because we were classified as an essential service. We currently expect that, should future orders be issued, we would be able to sustain our essential operations. Our third-party manufacturing supply chain for Accelerate Pheno systems and consumable test kits remains stable. However, the economic effects of the COVID-19 pandemic remain unpredictable, and we are closely monitoring the ability of all our suppliers to provide us with materials necessary for the manufacture of Accelerate Pheno systems and consumable test kits.
Additionally, the Company received loan proceeds of approximately $4.8 million under the Paycheck Protection Program established under the CARES Act. For additional information about the loan, refer to Item 1, Note 10, Long-Term Debt in this Form 10-Q.
We continue to monitor the rapidly evolving situation caused by the COVID-19 pandemic, and we may take further actions required by governmental authorities or that we determine are prudent to support the well-being of our employees, customers, suppliers, business partners and others. The degree to which the COVID-19 pandemic ultimately impacts our business, results of operations, cash flows and financial position will depend on future developments, which are highly uncertain, continuously evolving and cannot be predicted. This includes, but is not limited to, the duration and spread of the pandemic, its severity, the actions to contain the virus or treat its impact, and how quickly and to what extent normal economic and operating conditions can resume.
Accordingly, our current results and financial condition discussed herein may not be indicative of future operating results and trends. Refer to the section entitled “Risk Factors” in this Form 10-Q for additional risks we face due to the COVID-19 pandemic.
Changes in Results of Operations: Three and six months ended June 30, 2020 compared to three and six months ended June 30, 2019

| Three Months Ended June 30, |  |  |  |  | Six Months Ended June 30, |  |  |
| (in thousands) |  |  |  |  | (in thousands) |  |  |
| 2020 | 2019 | $ Change | % Change |  | 2020 | 2019 | $ Change | % Change
Net sales | $ | 2,125 |  | $ | 1,806 |  | $ | 319 |  | 18 | % |  | $ | 4,468 |  | $ | 3,557 |  | $ | 911 |  | 26 | %

For the three and six months ended June 30, 2020, total revenues increased as compared to the three and six months ended June 30, 2019 primarily due to increased sales of Accelerate PhenoTest BC Kits.
33

| Three Months Ended June 30, |  |  |  |  | Six Months Ended June 30, |  |  |
| (in thousands) |  |  |  |  | (in thousands) |  |  |
| 2020 | 2019 | $ Change | % Change |  | 2020 | 2019 | $ Change | % Change
Cost of sales | $ | 1,171 |  | $ | 907 |  | $ | 264 |  | 29 | % |  | $ | 2,459 |  | $ | 1,823 |  | $ | 636 |  | 35 | %
Gross profit | $ | 954 |  | $ | 899 |  | $ | 55 |  | 6 | % |  | $ | 2,009 |  | $ | 1,734 |  | $ | 275 |  | 16 | %

For the three and six months ended June 30, 2020, cost of sales and gross profit increased as compared to the three and six months ended June 30, 2019 as a result of higher sales. This increase was primarily driven by an increase in consumable inventory sales. Inventory without a cost basis was sold to customers for the three and six months ended June 30, 2020 and 2019. Pre-launch inventory previously not capitalized and expensed in a previous period for the three months ended June 30, 2020 and 2019, was $0.0 million and $0.1 million, respectively, and $0.1 million for each of the six months ended June 30, 2020 and 2019, respectively.
Cost of sales included non-cash equity-based compensation of $0.1 million for each of the three and six months ended June 30, 2020 and 2019.

| Three Months Ended June 30, |  |  |  |  | Six Months Ended June 30, |  |  |
| (in thousands) |  |  |  |  | (in thousands) |  |  |
| 2020 | 2019 | $ Change | % Change |  | 2020 | 2019 | $ Change | % Change
Research and development | $ | 5,347 |  | $ | 6,149 |  | $ | (802) |  | (13) | % |  | $ | 11,189 |  | $ | 13,083 |  | $ | (1,894) |  | (14) | %

Research and development expenses for the three and six months ended June 30, 2020 decreased compared to the three and six months ended June 30, 2019. The decrease was the result of a decrease in external studies spend, other cost containment measures, and employee non-cash equity-based compensation. Research and development expenses included non-cash equity-based compensation of $0.3 million and $0.8 million for the three months ended June 30, 2020 and 2019, respectively, and $1.5 million and $2.3 million for the six months ended June 30, 2020 and 2019, respectively.

| Three Months Ended June 30, |  |  |  |  | Six Months Ended June 30, |  |  |
| (in thousands) |  |  |  |  | (in thousands) |  |  |
| 2020 | 2019 | $ Change | % Change |  | 2020 | 2019 | $ Change | % Change
Sales, general and administrative | $ | 11,332 |  | $ | 12,837 |  | $ | (1,505) |  | (12) | % |  | $ | 24,275 |  | $ | 25,559 |  | $ | (1,284) |  | (5) | %

Sales, general and administrative expenses for the three and six months ended June 30, 2020 decreased as compared to the three and six months ended June 30, 2019. This decrease is primarily the result of multiple state and local governments implementing stay-at-home orders to respond to the spread of COVID-19 pandemic. As well as hospitals limiting access of their facilities to primarily focus on COVID-19 initiatives. These circumstances resulted in decreased expenses associated with travel, trade shows, and instrument demonstration expenses. In addition management also implemented additional cost containment initiatives to reduce other expenses such as services and marketing expenses.
These cost reductions were offset in part by increases in non-cash equity-based compensation expenses for the three and six months ended June 30, 2020 compared to the three and six months ended June 30, 2019. Sales, general and administrative expenses included non-cash equity-based compensation of $3.0 million and $2.0 million for the three months ended June 30, 2020 and 2019, respectively, and $6.0 million and $3.8 million for the six months ended June 30, 2020 and 2019, respectively. Non-cash equity-based compensation increased for the three and six months ended June 30, 2020 as compared to the three and six months ended June 30, 2019 due to larger stock options and stock awards granted to employees during the three months ended June 30, 2020.
34

| Three Months Ended June 30, |  |  |  |  | Six Months Ended June 30, |  |  |
| (in thousands) |  |  |  |  | (in thousands) |  |  |
| 2020 | 2019 | $ Change | % Change |  | 2020 | 2019 | $ Change | % Change
Loss from operations | $ | (15,725) |  | $ | (18,087) |  | $ | 2,362 |  | (13) | % |  | $ | (33,455) |  | $ | (36,908) |  | $ | 3,453 |  | (9) | %

For the three and six months ended June 30, 2020, our loss from operations decreased as compared to the three and six months ended June 30, 2019. The decreases were primarily the result of a decreases in research and development expenses, and sales, general and administrative expenses, combined with an increase in net sales as described above.
Loss from operations included non-cash equity-based compensation of $3.4 million and $2.9 million for the three months ended June 30, 2020 and 2019, respectively, and $7.6 million and $6.3 million for the six months ended June 30, 2020 and 2019, respectively.
This loss and further losses are anticipated and was the result of our continued investments in sales and marketing, key research and development personnel, related costs associated with product development, and commercialization of the Company’s products.

| Three Months Ended June 30, |  |  |  |  | Six Months Ended June 30, |  |  |
| (in thousands) |  |  |  |  | (in thousands) |  |  |
| 2020 | 2019 | $ Change | % Change |  | 2020 | 2019 | $ Change | % Change
Total other expense, net | $ | (3,505) |  | $ | (2,711) |  | $ | (794) |  | 29 | % |  | $ | (7,084) |  | $ | (5,390) |  | $ | (1,694) |  | 31 | %

Other expense for the three and six months ended June 30, 2020 increased as compared to the three and six months ended June 30, 2019. The increases were primarily the result of decreased interest income and increased interest expense for the three and six months ended June 30, 2020.
For the three months ended June 30, 2020 and 2019, the Company incurred interest expense associated with our Notes of $3.8 million and $3.5 million, respectively, and $7.6 million and $7.0 million for the six months ended June 30, 2020 and 2019, respectively.
These amounts were partially offset by investment income of $0.2 million and $0.8 million for the three months ended June 30, 2020 and 2019, respectively and $0.6 million and $1.7 million for the six months ended June 30, 2020 and 2019, respectively.

| Three Months Ended June 30, |  |  |  |  | Six Months Ended June 30, |  |  |
| (in thousands) |  |  |  |  | (in thousands) |  |  |
| 2020 | 2019 | $ Change | % Change |  | 2020 | 2019 | $ Change | % Change
Provision for income taxes | $ | — |  | $ | (17) |  | $ | 17 |  | NM |  | $ | — |  | $ | (238) |  | $ | 238 |  | NM

NM indicates percentage is not meaningful
For the three and six months end June 30, 2020, the Company did not carry an income tax provision amount as the Company does not recognize tax benefits from current year tax losses in the U.S. and other foreign jurisdictions. For the three and six June 30, 2019, the Company recorded tax provisions related to tax benefits from tax refunds generated by our foreign subsidiaries for international income taxes previously paid.
35

Capital Resources and Liquidity
Our primary source of liquidity has been from sales of shares of common stock and the issuance of our convertible notes. As of June 30, 2020, the Company had $88.7 million in cash and cash equivalents and investments, a decrease of $19.8 million from $108.5 million at December 31, 2019. The primary reason for the decrease was due to cash used in operations during the period.
The Company is subject to lease agreements. The future minimum lease payments under these lease agreements are included in Item 1, Note 16, Leases.
As of June 30, 2020, management believes that current cash balances will be sufficient to fund our capital and liquidity needs for the next twelve months.
Our primary use of capital has been for the commercialization and development of the Accelerate Pheno system. We believe our capital requirements will continue to be met with our existing cash balance and those provided by revenue, grants, exercises of stock options and/or additional issuance of equity or debt securities. However, if capital requirements vary materially from those currently planned, or if our business is negatively impacted by the COVID-19 pandemic more seriously or for longer than we currently expect, we may require additional capital sooner than expected. There can be no assurance that such capital will be available in sufficient amounts or on terms acceptable to us, if at all. Additional issuances of equity or convertible debt securities will result in dilution to our current common stockholders.
Summary of Cash Flows
The following summarizes selected items in the Company’s condensed consolidated statements of cash flows for the six months ended June 30, 2020 and 2019:

Cash Flow Summary |  |  |
| Six Months Ended June 30, |  |
| (in thousands) |  |
| 2020 | 2019 | $ Change
Net cash used in operating activities | $ | (27,395) |  | $ | (33,562) |  | $ | 6,167 |
Net cash provided by investing activities | 5,692 |  | 50,170 |  | (44,478) |
Net cash provided by financing activities | 8,038 |  | 4,620 |  | 3,418 |

Cash flows from operating activities
The net cash used in operating activities was $27.4 million and $33.6 million for the six months ended June 30, 2020 and 2019, respectively. Net cash used in operating activities was primarily the result of net losses offset by equity-based compensation and amortization of debt discount and issuance costs. These losses are the result of continued investments in research and development, sales and marketing, along with other factors. A decrease in our net loss, along with increases in non-cash expenses resulted in a decrease in cash used in operating activities for the six months ended June 30, 2020 compared to the prior year period.
Cash flows from investing activities
The net cash provided by investing activities was $5.7 million for the six months ended June 30, 2020. During the six months ended June 30, 2020, the Company purchased marketable securities of $21.5 million, which were offset in part by maturities of marketable securities of $27.8 million. The net cash provided by investing activities was $50.2 million for the three months ended June 30, 2019. During the six months ended June 30, 2019, the Company had proceeds from sales and maturities of marketable securities of $67.8 million, which were offset in part by purchases of marketable securities of $17.6 million.
The Company had an increase in marketable securities purchases during the six months ended June 30, 2020 compared to the six months ended June 30, 2019, due to the Company liquidating a portion of its money market funds carried as cash and cash equivalents as of December 31, 2019, and reinvesting these balances in debt securities available-for-sale during the six months ended June 30, 2020. The Company had larger proceeds
36

from sales and maturities of marketable securities for the six months ended June 30, 2019 compared to the six months ended June 30, 2020 due to the Company carrying larger balance of debt securities available-for-sale during the six months ended June 30, 2019.
Cash flows from financing activities
The net cash provided by financing activities was $8.0 million and $4.6 million for the six months ended June 30, 2020 and 2019, respectively. During the six months ended June 30, 2020 the Company collected $4.8 million in proceeds in connection with the PPP Note resulting in an increase in net cash provided by financing activities for the six months ended June 30, 2020.
Convertible Notes
On March 27, 2018, the Company issued $150.0 million aggregate principal amount of 2.50% Convertible Senior Notes (“Notes”). In connection with the offering of the Notes, the Company granted the initial purchasers of the Notes a 13-day option to purchase up to an additional $22.5 million aggregate principal amount of the Notes on the same terms and conditions. On April 4, 2018 the option was partially exercised, which resulted in $21.5 million of additional proceeds, for total proceeds of $171.5 million. The Notes mature on March 15, 2023, unless earlier repurchased or converted into shares of common stock subject to certain conditions. The Notes are convertible into shares of the Company’s common stock, can be repurchased for cash, or a combination thereof, at the Company’s election, at an initial conversion rate of 32.3428 shares of common stock per $1,000 principal amount of the Notes, which is equivalent to an initial conversion price of approximately $30.92 per share of common stock, subject to adjustment. We pay interest on the Notes semi-annually in arrears on March 15 and September 15 of each year with interest payments beginning on September 15, 2018. Proceeds received from the issuance of the Notes were allocated between long-term debt (the “liability component”) and contributed capital (the “equity component”), within the condensed consolidated balance sheet. The fair value of the liability component was measured using rates determined for similar debt instruments without a conversion feature. For additional information about the Notes, refer to Item 1, Note 11, Convertible Notes in this Form 10-Q.
In connection with the offering, we entered into a prepaid forward stock repurchase transaction (the “Prepaid Forward”) with a financial institution. Pursuant to the Prepaid Forward, we used approximately $45.1 million of the proceeds from the offering of the Notes to pay the prepayment amount. The aggregate number of our common stock underlying the Prepaid Forward is approximately 1,858,500 shares (based on the sale price of $24.25). The expiration date for the Prepaid Forward is March 15, 2023, although it may be settled earlier in whole or in part. Upon settlement of the Prepaid Forward, at expiration or upon any early settlement, the Forward Counterparty will deliver to us the number of shares of common stock underlying the Prepaid Forward or the portion thereof being settled early. The shares purchased under the Prepaid Forward were treated as treasury stock on the condensed consolidated balance sheet (and not outstanding for purposes of the calculation of basic and diluted earnings per share), but remain outstanding for corporate law purposes, including for purposes of any future stockholders' votes, until the Forward Counterparty delivers the shares underlying the Prepaid Forward to us.
Paycheck Protection Program (PPP) Loan
On April 14, 2020, the Company entered into a promissory note (the “PPP Note”) evidencing an unsecured loan in the amount of $4.8 million. The PPP Note matures on April 14, 2022 and bears interest at a rate of 1% per annum. Beginning November 14, 2020, the Company is required to make 18 monthly payments of principal and interest in the amount of $0.3 million. The PPP Note may be prepaid by the Company at any time prior to maturity with no prepayment penalties. The proceeds from the PPP Note may only be used for payroll costs (including benefits), interest on mortgage obligations, rent, utilities and interest on certain other debt obligations. For additional information about the PPP Note, refer to Item 1, Note 10, Long-Term Debt in this Form 10-Q.
Pursuant to the terms of the CARES Act and the PPP, the Company may apply to the lender for forgiveness for the amount due on the Loan. The amount eligible for forgiveness is based on the amount of loan proceeds used by the Company (during the 24 week period after the lender makes the first disbursement of loan proceeds) for the payment of certain covered costs, including payroll costs (including benefits), rent and utilities, subject to certain limitations and reductions in accordance with the CARES Act and the PPP. No assurance can be given that the Company will obtain forgiveness of the PPP Note in whole or in part. As of June 30, 2020 the Company had not applied for forgiveness.
37

Contractual Obligations
A table reflecting certain of our specified contractual obligations as of December 31, 2019 was provided in the Management’s Discussion and Analysis of Financial Condition and Results of Operation of our 2019 Form 10-K. During the three months ended June 30, 2020, the Company entered into the PPP Note in the amount of $4.8 million. The PPP Note matures on April 14, 2022 and bears interest at a rate of 1% per annum. Beginning November 14, 2020, the Company is required to make 18 monthly payments of principal and interest in the amount of $0.3 million. The PPP Note may be prepaid by the Company at any time prior to maturity with no prepayment penalties. For additional information about the PPP Note, refer to Item 1, Note 10, Long-Term Debt in this Form 10-Q.
With the exception of this item, there were no material changes outside the ordinary course of our business in the specified contractual obligations during the three months ended June 30, 2020.
Off-Balance Sheet Arrangements
We did not have any off-balance sheet arrangements as of June 30, 2020.
Critical Accounting Policies and Estimates
Our discussion and analysis of our financial condition and results of operations are based upon our unaudited condensed consolidated financial statements, which have been prepared in accordance with U.S. GAAP. The preparation of these financial statements requires us to make certain estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses. We evaluate our estimates on an ongoing basis, including those related to accounts receivable, inventories, property and equipment, intangible assets, accruals, warranty liabilities, tax valuation accounts and stock-based compensation. We base our estimates on historical experience and on various other assumptions we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and are not readily apparent from other sources. Actual results may differ from these estimates. Our critical accounting policies and estimates are discussed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2019. Additional critical accounting policies added to Note 1, Organization and Nature of Business; Basis of Presentation; Principles of Consolidation; Significant Accounting Policies include the Company's accounting policy relating to the PPP Note recorded during the three months ended June 30, 2020.
Item 3. Quantitative and Qualitative Disclosures About Market Risk
Interest Rate Risk
Our investment portfolio is exposed to market risk from changes in interest rates. The fair market value of fixed rate securities may be adversely impacted by fluctuations in interest rates while income earned on floating rate securities may decline as a result of decreases in interest rates. We have historically maintained a relatively short average maturity for our investment portfolio, and we believe a hypothetical 100 basis point adverse move in interest rates along the entire interest rate yield curve would change the fair value of our interest sensitive financial instruments by approximately $0.0 million as of June 30, 2020 and $0.3 million as of December 31, 2019.
Under our current policies, we do not use interest rate derivative instruments to manage exposure to interest rate changes. We attempt to ensure the safety and preservation of our invested principal funds by limiting default risk, market risk and reinvestment risk. The goals of our investment policy are preservation of capital, fulfillment of liquidity needs and fiduciary control of cash and investments. We also seek to maximize income from our investments without assuming significant risk. To achieve our goals, we maintain a portfolio of cash equivalents and investments in a variety of securities that management believes to be of high credit quality. Further information regarding our investments is included in Item 1, Note 5, Investments in this Form 10-Q.
Although the Company’s Notes are based on a fixed rate, changes in interest rates could impact the fair market value of the Notes. As of June 30, 2020, the fair market value of the Notes was $122.8 million. For additional information about the Notes, refer to Item 1, Note 11, Convertible Notes in this Form 10-Q.
38

Foreign Currency Risk
We operate primarily in the U.S. and a majority of our cost, expense and capital purchasing activities for the six months ended June 30, 2020 were transacted in U.S. dollars. As a corporation with international and domestic operations, we are exposed to changes in foreign exchange rates. Our international revenue is predominantly in Europe and the Middle East and is denominated in Euros and U.S. dollars. In our international operations, we pay payroll and other expenses in local currencies. Our exposures to foreign currency risks may change over time and could have a material adverse impact on our financial results.
Item 4. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
Based on an evaluation under the supervision and with the participation of the Company’s management, the Company’s Principal Executive Officer and Principal Financial Officer have concluded that the Company’s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) were effective as of June 30, 2020, to ensure that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is (i) recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and (ii) accumulated and communicated to the Company’s management, including its Principal Executive Officer and Principal Financial Officer, as appropriate to allow timely decisions regarding required disclosure.
Changes in Internal Control Over Financial Reporting
There was no change in the Company’s internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) during the quarter ended June 30, 2020 that materially affected, or is reasonably likely to materially affect, the Company’s internal control over financial reporting.
39

PART II - OTHER INFORMATION
Item 1. Legal Proceedings
We are from time to time subject to various claims and legal actions in the ordinary course of our business. We believe that there are currently no claims or legal actions that would reasonably be expected to have a material adverse effect on our results of operations or financial condition.
Item 1A. Risk Factors
In addition to the other information set forth in this Form 10-Q, you should carefully consider the risks discussed in the section entitled “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2019 and the risks relating to the impact of the COVID-19 pandemic described below. The risks described in our Annual Report on Form 10-K for the year ended December 31, 2019 and below are not the only risks facing the Company. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial may also materially adversely affect our business, results of operations, cash flows and financial position.
Additional Risk Related to Our Business and Strategy
The COVID-19 pandemic has had, and is expected to continue to have, a significant adverse impact on our commercial operations and also exposes our business to other risks.
In late 2019, a novel strain of coronavirus (COVID-19) was reported to have surfaced in Wuhan, China, which has since spread globally. In March 2020, the World Health Organization declared COVID-19 a global pandemic. Further, the COVID-19 outbreak has resulted in government authorities around the world implementing numerous measures to try to reduce the spread of COVID-19, such as travel bans and restrictions, quarantines, shelter-in-place, stay-at-home, or total lock-down (or similar) orders and business limitations and shutdowns. For example, the State of Arizona has implemented several orders promoting physical distancing, limiting certain activities, and restricting the operations of certain businesses, including restaurants, bars, gyms, theaters and water parks. The COVID-19 pandemic and these measures have caused, and are continuing to cause, business slowdowns or shutdowns in affected areas, both regionally and worldwide, which have significantly impacted our business and results of operations, starting in the first quarter of 2020. For example, this included diminished access to our customers, including hospitals, which has severely limited our ability to sell or implement the Accelerate Pheno systems, as well as a modestly negative impact to the demand for our consumable test kits beginning in April 2020. In addition, in April and May 2020 our Accelerate Pheno kit orders declined as many hospitals curtailed elective surgeries to respond to COVID-19. Since May 2020, our Accelerate Pheno kit orders have returned to more normal levels, but could decline again if COVID-19 surges cause hospitals to reduce or prohibit elective surgeries. For additional information, refer to “COVID-19 Update” in Part I, Item 2 of this Form 10-Q.
In addition to the negative impact on new sales and implementations of the Accelerate Pheno system and to demand for our consumable test kits, the pandemic exposes our business, operations, and workforce to a variety of other risks, including:
•delays in product development or reductions in manufacturing production as a result of inventory shortages, supply chain shortages, or diversion of our efforts and resources to projects related to COVID-19;
•increased expenses resulting from our COVID-19 BioCheck serology initiative;
•interruptions, availability or delays in global shipping to transport our products;
•regulatory approval delays due to regulators being overwhelmed reviewing COVID-19 related medical devices and drugs;
•increased regulatory restrictions or continued market volatility could hinder our ability to execute strategic business activities, as well as negatively impact our stock price;
40

•significant disruption of global financial markets, which could cause fluctuations in currency exchange rates or negatively impact our ability to access capital markets;
•inability to access capital markets on terms that are not significantly detrimental to our business because our revenue growth rate has slowed due to our inability to sell and implement the Accelerate Pheno system as forecasted prior to the pandemic at a stage in our maturation when we are cash flow negative and have significant indebtedness in the form of convertible senior notes;
•negative impact on our workforce productivity, product development, and research and development due to difficulties resulting from our personnel working remotely; and
•illnesses to key employees, or a significant portion of our workforce, which may result in inefficiencies, delays, and disruptions in our business;
Any of these developments may adversely affect our business, harm our reputation, or result in legal or regulatory actions against us.
Further, the spread of COVID-19 has caused us to modify our business practices (including employee travel, employee work locations, and cancellation of physical participation in meetings, events and conferences), and we may take further actions as may be required by government authorities or that we determine are in the best interests of our employees, customers, partners, and suppliers. There is no certainty that such measures will be sufficient to mitigate the risks posed by the virus, and our ability to perform critical functions could be harmed.
Additionally, COVID-19 could affect our internal controls over financial reporting as a portion of our workforce is required to work from home and therefore new processes, procedures, and controls could be required to respond to changes in our business environment.
The potential effects of COVID-19 may also impact many of our other risk factors discussed in in Part I, Item 1A, Risk Factors, in our Annual report on Form 10-K for the year ended December 31, 2019. The degree to which COVID-19 ultimately impacts our business, results of operations, cash flows and financial position will depend on future developments, which are highly uncertain, continuously evolving and cannot be predicted, including, but not limited to, the duration and spread of the COVID-19 outbreak, its severity, the actions to contain the virus or treat its impact and how quickly and to what extent normal economic and operating conditions can resume.
Item 2. Unregistered Sales of Equity Securities and Use of Proceeds
None.
Item 3. Defaults Upon Senior Securities
Not applicable.
Item 4. Mine Safety Disclosures
Not applicable.
Item 5. Other Information
None.
41

Item 6. Exhibits

Exhibit No. | Description | Filing Information
3.1 | Certificate of Incorporation of Registrant | Incorporated by reference to Appendix B to the Registrant’s Definitive Proxy Statement on Schedule 14A filed on November 13, 2012
3.1.1 | Certificate of Amendment to Certificate of Incorporation of Registrant | Incorporated by reference to Exhibit A to the Registrant’s Definitive Information Statement on Schedule 14C filed on July 12, 2013
3.1.2 | Certificate of Amendment to Certificate of Incorporation of Registrant | Incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on March 15, 2016
3.1.3 | Certificate of Amendment to the Certificate of Incorporation of Registrant | Incorporated by reference to Exhibit 3.1 to the Registrant’s Current Report on Form 8-K filed on May 15, 2019
3.2 | Amended and Restated Bylaws of Registrant | Incorporated by reference to Exhibit 3.2 to the Registrant’s Current Report on Form 8-K filed on August 8, 2019
10.1 | 2020 Salary Waiver and Nonqualified Stock Option Grant Plan | Incorporated by reference to Exhibit 10.1 to the Registrant's Current Report on Form 8-K filed on April 8, 2020
10.2 | Form of 2020 Salary Waiver Agreement | Incorporated by reference to Exhibit 10.2 to the Registrant's Current Report on form 8-K filed on April 8, 2020
10.3 | Promissory Note, dated April 14, 2020, by and between Registrant and Zions | Incorporated by reference to Exhibit 10.1 to the Registrant's Current Report on Form 8-K filed on April 20, 2020
10.4 | Consulting Services Agreement by and between Registrant and Romney Humphries, dated May 5, 2020 | Filed herewith
10.5 | Sixth Amendment to the Accelerate Diagnostics, Inc. 2012 Omnibus Equity Incentive Plan | Incorporated by reference to Exhibit 10.1 to the Registrant's Current Report on Form 8-K filed on May 14, 2020
31.1 | Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | Filed herewith
31.2 | Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 | Filed herewith
32 | Certification of Principal Executive Officer and Principal Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 | Furnished herewith
101.INS | XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document | Filed herewith
101.SCH | Inline XBRL Taxonomy Extension Schema Document | Filed herewith
101.CAL | Inline XBRL Taxonomy Extension Calculation Linkbase Document | Filed herewith
101.DEF | Inline XBRL Taxonomy Extension Definition Linkbase Document | Filed herewith
101.LAB | Inline XBRL Taxonomy Extension Label Linkbase Document | Filed herewith
101.PRE | Inline XBRL Taxonomy Extension Presentation Linkbase Document | Filed herewith
104 | Cover Page Interactive Data File (formatted as Inline XBRL with applicable taxonomy extension information contained in Exhibits 101) | Filed herewith

42

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned thereunto duly authorized.
ACCELERATE DIAGNOSTICS, INC.

August 7, 2020 | /s/ Jack Phillips
| Jack Phillips President and Chief Executive Officer
| (Principal Executive Officer)
August 7, 2020 | /s/ Steve Reichling
| Steve Reichling Chief Financial Officer
| (Principal Financial and Accounting Officer)

43